

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/72, C12N 15/10, A61K 38/17		A1	(11) International Publication Number: WO 99/19354 (43) International Publication Date: 22 April 1999 (22.04.99)
(21) International Application Number: PCT/SE98/01548 (22) International Filing Date: 31 August 1998 (31.08.98) (30) Priority Data: 9703745-1 14 October 1997 (14.10.97) SE 9801148-9 31 March 1998 (31.03.98) SE (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN AB [SE/SE]; S-112 87 Stockholm (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): BERKENSTAM, Anders [SE/SE]; Långholmsgatan 11, S-117.33 Stockholm (SE). DAHLBERG, Mats [SE/SE]; Sankt Göransgatan 64, S-112 87 Stockholm (SE). (74) Agents: TANNERFELDT, Agneta et al.; Pharmacia & Upjohn AB, S-112 87 Stockholm (SE).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: NOVEL VITAMIN D RECEPTOR RELATED POLYPEPTIDES, NUCLEIC ACID SEQUENCE ENCODING THE SAME AND USES THEREOF (57) Abstract <p>The present invention relates to novel vitamin D receptor related (VDRR) polypeptides, and formulations containing the same. Nucleic acid sequences encoding the VDRR polypeptides, expression vectors containing such sequences and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel VDRR polypeptides of the invention. The invention further relates to VDRR polypeptides for use as medicaments, and use of substances affecting VDRR signal transduction for the manufacture of medicaments for treating metabolic, proliferative or inflammatory conditions. The present invention also relates to methods for identifying clones encoding a VDRR polypeptide, methods for identifying ligands to a VDRR and methods for identifying substances for treatment of conditions affected by a VDRR polypeptide. More specifically, the novel VDRR polypeptide can be the polypeptide designated VDRRγ, which may be regulated by any small chemical molecule similar in structure to known ligands for nuclear receptors.</p>			

20084
#16

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

NOVEL VITAMIN D RECEPTOR RELATED POLYPEPTIDES. NUCLEIC ACID
SEQUENCE ENCODING THE SAME AND USES THEREOF

5 FIELD OF THE INVENTION

The present invention relates to novel vitamin D receptor related (VDRR) polypeptides. Nucleic acid sequences encoding the same, expression vectors containing such sequences and host cells transformed with such expression vectors are also disclosed, as are
10 methods for the expression of the novel VDRR polypeptides of the invention, and uses thereof.

BACKGROUND OF THE INVENTION

15 Nuclear hormone receptors is a large group of conditionally regulated transcription factors. These receptors are activated and regulate target gene expression in response to binding a variety of small chemical molecules (ligands) including steroids, vitamin D3, retinoids, eicosanoids (prostanoids), thyroid hormone and cholesterol derivatives.

A growing number of structurally related receptors have been identified for which no
20 ligands yet have been identified. This group of receptors is referred to as orphan nuclear receptors (ONRs). A review of the ONRs can be found in Enmark et al, Mol. Endo., vol. 10, No. 11 (1996) pp. 1293-1307, which is hereby incorporated by reference. The pivotal importance of a number of ONRs for processes such as metabolic homeostasis, cell differentiation and development have been demonstrated both by biochemical and genetic
25 techniques. In addition, several ONRs have also been implicated as key factors in a variety of common diseases and disorders such as diabetes, obesity, inflammatory conditions and proliferative diseases.

Based on these findings it is generally believed that novel ONRs are going to become potential drug targets for therapeutic invention of common diseases. Thus, it is of great
30 importance to identify such receptors.

SUMMARY OF THE INVENTION

The present invention relates to novel vitamin D receptor related (VDRR) polypeptides, and formulations containing the same. Nucleic acid sequences encoding the VDRR polypeptides, expression vectors containing such sequences and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel VDRR polypeptides of the invention. The invention further relates to VDRR polypeptides for use as medicaments, and use of substances affecting VDRR signal transduction for the manufacture of medicaments for treating metabolic, proliferative or inflammatory conditions. The present invention also relates to methods for identifying clones encoding a VDRR polypeptide, methods for identifying ligands to a VDRR and methods for identifying substances for treatment of conditions affected by a VDRR polypeptide. More specifically, the novel VDRR polypeptide can be the polypeptide designated VDRR γ , which may be regulated by any small chemical molecule similar in structure to known ligands for nuclear receptors.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 - The cDNA sequence encoding the novel nuclear receptor polypeptide vitamin D receptor related gamma (VDRRg) is shown.

Figure 2 - Evolutionary neighbor-joining tree for VDRRg as given by DBD-HMM alignment.

Figure 3 - Evolutionary neighbor-joining tree for VDRRg as given by LBD-HMM alignment.

Figure 4 - The deduced amino acid sequence of VDRRg is shown.

Figure 5 - Expression of VDRRg in adult human tissues. The numbers on the right hand side, refer to kilobasepairs of the mRNA.

Figure 6 - Vitamin D3 transactivate a GAL4-DBD/VDR-LBD fusion protein but not a GAL4-DBD/VDRR γ -LBD fusion protein in transient transfections of CV-1 cells. The number on the left hand side refer to relative luciferase activity of the GAL4-luciferase reporter gene.

Figure 7 - The cDNA sequence encoding VDRRg-2 with an alternatively spliced 5'-end compared to VDRRg is shown.

Figure 8 - The deduced amino acid sequence of VDRRg-2 is shown.

Figure 9 - Heterodimerization of VDRRg with a retinoid X receptor (RXR) is shown.

5 Figure 10 - The effect of pregnenolone derivatives as activators of VDRRg are shown.

Figure 11 - The effect of pregnenolone 16 α -carbonitrile (PCN), dexamethasone and an antiprogesterin (RU486) as activators of VDRRg are shown.

10 Figure 12 - Percent similarity between the new genes VDRRg-1 and VDRRg-2 and the known genes XOR-6, HVDR, CAR-1 and CAR-2.

Figure 13 - Percent identity between the new genes VDRRg-1 and VDRRg-2 and the known genes XOR-6, HVDR, CAR-1 and CAR-2.

15

DETAILED DESCRIPTION OF THE INVENTION

The objects above are met by the present invention, which relates to a mammalian, preferably human, isolated or recombinant nucleic acid comprising a contiguous nucleic acid
20 sequence encoding a vitamin D receptor related (VDRR) polypeptide. The VDRR polypeptide is suitably origin.

In preferred embodiments of the present invention, the nucleic acid encoding the VDRR polypeptide contains a DNA-binding domain (DBD) comprising about 77 amino acids with 9 cysteine residues. The DBD is further characterized by the following amino
25 acid sequence similarity relative to the DBDs of human Vitamin D Receptor (hVDR) and Orphan Nuclear Receptor 1 isolated from *Xenopus laevis* (xONR1 = XOR-6), respectively:
(i) at least about 60% amino acid sequence similarity with the DBD of hVDR; and
(ii) at least about 65% amino acid sequence similarity with the DBD of xONR1.
More particularly, the amino acid sequence similarity relative to the DBDs of hVDR and
30 xONR1, respectively is
(i) about 65% amino acid sequence similarity with the DBD of hVDR; and

(ii) about 71% amino acid sequence similarity with the DBD of xONR1.

In preferred embodiments of the present invention, the nucleic acid encoding the VDRR polypeptide contains a ligand-binding domain (LBD) characterized by the following amino acid sequence similarity, relative to the LBDs of hVDR and xONR1, respectively:

- 5 (i) at least about 30% amino acid sequence similarity with the LBD of hVDR, suitably at least 35% amino acid sequence similarity with the LBD of hVDR; and
(ii) at least about 40% amino acid sequence similarity with the LBD of xONR1, suitably at least 45% amino acid sequence similarity with the LBD of xONR1.

More particularly, the amino acid sequence similarity relative to the LBDs of hVDR and
10 xONR1, respectively is

- (i) about 42% amino acid sequence similarity with the LBD of hVDR; and
(ii) about 54% amino acid sequence similarity with the LBD of xONR1.

“amino acid sequence similarity” refers to: $100 \times \text{Consensus Length} / (\text{Consensus Length} + \text{Mismatches} + \text{Gaps})$.

15 The term amino acid sequence identity can also be used. Amino acid sequence identity is calculated by comparing the absolute amino acid residue identity. In Figure 13 the amino acid sequence identity between the new genes VDRRg-1 and VDRRg-2 and the known genes are shown.

In particularly preferred embodiments, the nucleic acid sequences of the present
20 invention are substantially the same as those given in Fig. 1 or Fig. 7, the same or alleles thereof.

The present invention also relates to a nucleic acid probe for the detection of a nucleic acid sequence encoding a VDRR polypeptide in a sample. Suitably, the probe comprises at least 14 contiguous nucleotides, and preferably at least 28 contiguous nucleotides, of the nucleic acid sequences given in Fig. 1 or Fig. 7. The nucleic acid probe can be
25 used in a method for identifying clones encoding a VDRR polypeptide, wherein the method comprises screening a genomic or cDNA library with the probe under low stringency hybridization conditions, and identifying those clones which display a substantial degree of hybridization to said probe.

30 The present invention further relates to an isolated or recombinant VDRR polypeptide. The polypeptide can be full-length, at which the sequence of amino acids is identical to

the corresponding sequence found in mammals in general, and in human beings in particular. In the present invention, the polypeptide can also be a truncated, extended or mutated form of the full-length polypeptide. Truncated and extended forms relate to VDRR polypeptides where one or more amino acids are missing or have been added, respectively, at the N terminal end of the polypeptide chain. Mutated forms relate to VDRR polypeptides where one or more amino acid has been substituted by another amino acid. Suitably, the isolated or recombinant VDRR polypeptide exhibits the amino acid sequences given in Fig. 4 or Fig. 8.

The N-terminal sequence of the present nucleic acids encoding VDRR polypeptides, as well as the amino acid sequence of the present VDRR polypeptides, may vary. Thus, various N-terminal isoforms are envisaged, e.g. any of $\alpha 1$, $\alpha 2$, $\beta 1$, $\beta 2$, $\beta 3$, $\beta 4$, $\gamma 1$ or $\gamma 2$ as disclosed in Fig. 7B of Transcription Factors 3: nuclear receptors, Protein Profile, vol. 2, issue 11 (1995), pp. 1173-1235. This review of nuclear receptors generally is hereby incorporated by reference. More specifically, Vitamin D receptors and related orphans, e.g. ONR1, are discussed at p. 1191-1992.

The present invention further relates to pharmaceutical formulations comprising an isolated or recombinant VDRR polypeptide, and one or more therapeutically acceptable excipients. Examples of excipients that can be used are carbohydrates, e.g. monosaccharides, disaccharides and sugar alcohols, such as saccharose and sorbitol. Further examples include amino acids, e.g. histidine and arginine, surfactants, e.g. polyoxyethylene sorbitan fatty acid esters, inorganic salts, e.g. sodium chloride and calcium chloride, and complexing agents, e.g. EDTA and citric acid.

The present formulation can be in the form of an aqueous solution ready-for-use, or dried, particularly lyophilized. In the latter case, the formulation is reconstituted with a liquid, e.g. sterile water or saline, before use.

The present invention further relates to an expression vector comprising an isolated or recombinant nucleic acid, the nucleic acid comprising a contiguous nucleic acid sequence encoding a Vitamin D receptor related (VDRR) polypeptide. The invention also relates to a cell containing such an expression vector.

The present invention further relates to a cell containing the claimed nucleic acid, the nucleic acid comprising a contiguous nucleic acid sequence encoding a Vitamin D receptor related (VDRR) polypeptide.

The present invention further relates to a process for recombinant production of a
5 VDRR polypeptide, by expressing the claimed isolated or recombinant contiguous nucleic acid sequence encoding a Vitamin D receptor related (VDRR) polypeptide in a suitable host cell, preferably an eukaryotic cell.

The present invention further relates to method for identifying a ligand to a VDRR, e.g. by a cell-based reporter assay, transgenic-animal reporter assay or *in vitro*-binding
10 assay. It also relates to a method for identifying a substance for treatment of a condition affected by a VDRR polypeptide, comprising screening for an agonist or an antagonist of VDRR polypeptide signal transduction to be used for treating metabolic, proliferative or inflammatory conditions.

The present invention further relates to a VDRR polypeptide for use as a medica-
15 ment, as well as use of a substance affecting VDRR signal transduction for the manufacture of a medicament for treating metabolic, proliferative or inflammatory conditions. More particularly, the present invention can be used for the manufacture of medicaments for treating obesity, diabetes, anorexia, lipoprotein defects, hyperlipidemia, hypercholesteremia or hyperlipoproteinemia. The present invention can be used also for the manufacture of
20 medicaments for treating osteoporosis, rheumatoid arthritis, benign and malign tumors, hyperproliferative skin disorders or hyperparathyroidism.

The present invention further relates to a method for treating metabolic, proliferative or inflammatory conditions by introducing into a mammal a nucleic acid vector encoding for expression of a VDRR polypeptide. The nucleic acid vector is capable of transforming a
25 cell *in vivo* and expressing said polypeptide in said transformed cell.

The present invention further relates to a method for treatment of a metabolic, proliferative or inflammatory condition by administration of a therapeutically effective amount of a substance affecting VDRR signal transduction, specifically a VDRR polypeptide.

In the present invention, the term "isolated" in connection with VDRR polypeptides
30 or nucleic acids encoding the same, relates to nucleic acids or polypeptides that have been isolated from a natural source, e.g. the liver, small intestine or colon of a human being. The

isolated VDRR polypeptides or nucleic acids of the present invention are unique in the sense that they are not found in a pure or separated form in nature. Use of the term "isolated" indicates that a naturally occurring sequence has been removed from its normal cellular environment. Thus, the sequence may be in a cell-free environment or in a different cellular environment. The term does not imply that the sequence is the only nucleic acid or amino acid sequence present, but that it is the predominant nucleic acid or amino acid sequence present. Furthermore, the nucleic acid or polypeptide should be essentially free of non-amino acid or non-nucleic acid material naturally associated with the respective product. In this context, essentially free relates to more than 80%, suitably more than 90%, and preferably more than 95% purity.

The term "substantially the same" when referring to the nucleic acid sequences in Fig 1 or Fig 7 and when referring to the amino acid sequences in Fig. 4 or Fig.8 means that they are derived from the sequences given in the figures and have the same function as those.

The inventors of the present invention, have surprisingly isolated a novel nucleic acid sequence, and a polypeptide encoded by said nucleic acid sequence. Thus, a novel cDNA encoding a polypeptide designated VDRR γ has been cloned and characterized. This polypeptide is, based on amino acid sequence similarity, a novel member of the nuclear (hormone) receptor supergene family. Hidden Markov Models (HMMs) in combination with phylogenetic analysis such as neighbor-joining tree methods and other statistical algorithms shows that VDRR γ belong to a sub-family of vitamin D receptors (VDRs) and a VDR-like receptor from *Xenopus laevis* designated xONR1 (see Smith et al., Nucl. Acids Res., 22 (1994), No. 1, pp. 66-71) or XOR-6 as in WO96/22390. The VDRR γ , therefore, is one member of a family of Vitamin D receptor related (VDRR) polypeptides.

The degree of amino acid similarity in the DBD and LBD of VDRR γ as compared to the most closely related receptors XOR-6, hVDR and CAR (see WO 93/17041) is similar to the relationship between other distinct, but related nuclear receptors. (See Fig.12). The thyroid hormone (TRb) and retinoic acid receptor (RARb) are approximately 60% and 40% identical at the amino acid level in the DBD and LBD, respectively. By comparison, the closely related but unique genes encoding human RARa and RARb nuclear receptors are 97% and 82% identical in the DBD and LBD, respectively.

As recognized by those skilled in the art of nuclear receptors, the DBD displays the highest degree of conservation (amino acid identity) both between different nuclear receptors (paralogous) and between identical receptors from different species (orthologues). The two “zink-fingers” in the DBD are generated by two evolutionary conserved amino acid motifs

5 Cys-X2-Cys-X13-Cys-X2-Cys (amino-terminal or first zink-finger) and Cys-Xn-Cys-X9-Cys-X2-Cys (carboxy-terminal or second zink-finger) in which two pairs of cysteins chelate on zink ion. The vast majority of nuclear receptors have five amino acid residues between the first two Cys residues in the second zink-finger (Cys-X5-Cys-X9-Cys-X2-Cys) see Gronemeyer and Laudet (Protein Profile 1995, 2, issue 11) for details. The today only

10 known exception to this rule are the PPARs which have three amino acid (Cys-X3-Cys-X9-Cys-X2-Cys) residues and the TLL group of receptors which have seven (Cys-X7-Cys-X9-Cys-X2-Cys). Thus another feature which is characteristic of the novel VDRRg polypeptide described herein is that the number of amino acid residues in this part of the DBD is six (Cys-X6-Cys-X9-Cys-X2-Cys) as shown in Figs.4 and 8. Today, the only other nuclear

15 receptor like sequences found in the TREMBLE data base with the same number of amino acid residues between the two cys residues are two sequences (Q20097 and Q18155) from the worm *C. elegans* (Q20097 and Q18155). However, the entire DBD of these putative *C. elegans* nuclear receptors are only distantly related to the DBD of VDRRg. Taken together, the comparison of the DBD and LBD of the nuclear receptor VDRRg described herein (See

20 Fig.12), clearly demonstrate that this receptor is a novel member of the nuclear receptor super-gene family which is distinct from other known nuclear receptors that are most closely related to the VDRRg including ONR-1 (in Smith et al., 1994, Nucleic Acids Res., 22, pp66-71) or XOR-6 (in WO 96/22390), hVDR and CAR (WO 93/17041).

This finding, in combination with the highly restricted expression pattern we observe for

25 human VDRRγ (liver, small intestine and mucosa of colon) and in analogy to other nuclear receptors exhibiting a tissue specific expression pattern such as the peroxisome proliferator-activated receptors (PPARs) - suggest that VDRRγ performs important physiological functions in liver, small intestine and colon. Accordingly, VDRRγ is likely to be an important sensor of key metabolic pathways affecting lipid, carbohydrate or amino acid

30 metabolism/homeostasis. In addition, the highly selective tissue specific expression pattern

suggest that VDRR γ may participate in cellular differentiation and development of these tissues.

An additional human VDRR γ cDNA with an alternatively spliced 5'-end has been identified (see Fig. 7). The VDRR γ cDNAs are thus able to encode at least one alternative
5 N-terminal variant (Fig. 8) in addition to the VDRR γ polypeptide shown in Fig. 4. In analogy to other members of the nuclear receptor supergene family such as ROR α and RAR α these N-terminal isoforms of VDRR γ may specify different functions including DNA-binding specificity and/or promoter specific activation (Gronemeyer and Laudet, 1995).

10 In the present specification, the term VDRR γ relates to the various polypeptides corresponding to the differentially spliced VDRR γ cDNAs including VDRR γ -1 and VDRR γ -2. However, when reference is made to Fig. 1 and Fig. 4, VDRR γ cDNA and VDRR γ relates specifically to VDRR γ -1 cDNA and VDRR γ -1, respectively. In the same way, when reference is made to Fig. 7 and Fig. 8, VDRR γ cDNA and VDRR γ relates
15 specifically to VDRR γ -2 cDNA and VDRR γ -2, respectively.

In contrast to the VDRR γ -2 cDNA, the VDRR γ -1 cDNA does not contain a classical AUG initiation codon but instead may initiate at an alternative CUG codon. This putative non-AUG start site is located in a favorable sequence context for efficient initiation from alternative start sites and is in frame with the entire open reading frame and preceded by a
20 stop codon.

Taken together, the VDRRs in general, and more specifically the VDRR γ , may be important in

- 1) metabolic diseases such as obesity, diabetes (type I and II), lipoprotein disorders,
- 2) proliferative conditions such as tumors (benign and malignant) of the small
25 intestine and colon,
- 3) ulcero-inflammatory diseases of small intestine and colon such as Crohn's disease and ulcerative colitis, and
- 4) congenital anomalies of small intestine and colon.

The high amino acid sequence identity of VDRR γ with the VDR both in the DNA-
30 binding domain (DBD) and ligand-binding domain (LBD) indicate that these two receptors

may also have overlapping yet distinct functional characteristics. In analogy, retinoic acid receptors (RARs) and retinoid X receptors (RXRs) have similar amino acid sequence identities in the DBD and LBD region as the VDR and VDRR γ . RARs and RXRs have been shown to have distinct functional similarities such that both receptors bind 9-cis retinoic acid and have overlapping DNA-binding specificities and accordingly regulate overlapping gene networks. Based on these findings, VDRR γ may be regulated by small chemical molecules similar in structure to known ligands for nuclear receptors but not necessarily identical to ligands for the 1 α , 25-dihydroxy vitamin D3 receptor. Furthermore, VDRR γ may regulate vitamin D3 responsive gene networks by binding to a Vitamin D responsive element (VDRE)-like DNA sequence. In the present application, the 1 α , 25-dihydroxy vitamin D3 receptor is abbreviated as the Vitamin D receptor (VDR).

In the present invention, the substance affecting VDRR signal transduction can be any small chemical molecule of natural or synthetic origin, e.g. a carbohydrate such as an aromatic compound. The small molecule may have a molecular weight in the range of from about 100 up to about 500 Da. Suitably, the small chemical molecule has a molecular weight in the range of from 200 up to 400 Da. Preferably, the small chemical molecule has a molecular weight of about 300 Da.

The human VDRR γ polypeptides, including VDRR γ -1 and VDRR γ -2, have been shown to be activated e.g. by pregnenolones and estradiol (weakly), but not by certain other steroid hormones such as cortisol, aldosterone, progesterone and estrogen, and most likely not by progestines and glucocorticoids. Thus, human VDRR γ is not activated by pregnenolone 16 α -carbonitrile (PCN), a glucocorticoid antagonist. For this reason, human VDRR γ can also be designated human pregnenolone activated (nuclear) receptors (hPAR). Information about pregnenolone can be found e.g. in the Merck Index, 11th ed., Merck & Co., Inc. Rahway, N.J., USA, p. 7735, 1989.

Activators for human VDRR γ polypeptides, including VDRR γ -1 and VDRR γ -2, (hPAR-1 and hPAR-2, respectively), include but are not limited to pregnenolones, such as pregnane-ones, pregnane-diones, pregnane-triones, and pregnane-diols, and androstanes, such as androstane-ols, and androstane-diols. Suitably, the pregnenolones are non-planar, particularly 5 β -pregnanes.

Specific examples of activators and possibly ligands for human VDRR γ polypeptides, including VDRR γ -1 and VDRR γ -2, are the following compounds, which are marketed by Sigma-Aldrich of Sweden:

- i) 5 β -pregnane-3,20-dione
- 5 ii) 3 α -hydroxy-5 β -pregnane-11,20-dione methanesulphonate
- iii) 5 β -pregnane-3 α ,20 β -diol
- iv) pregnenolone
- v) Pregn-4-eno[16,17- δ][2]isoxazolline-3,20-dione, 6 α -methyl-3'-phenyl-, ethyl ether solvate
- 10 vi) Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-[6-methoxy-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]-16-methyl-, (16 α)-
- vii) Estran-3-ol, 17-[[[3-(trifluoromethyl)phenyl]methyl]amino]-, (E)-2-butenedioate (1:1) (salt)
- viii) 9 α -Fluoro-5 α -androstane-11 β ,17 β -diol
- 15 ix) Spiro[5 α -androstane-3,2'-benzothiazolin]-11-one, 17 β -hydroxy-17-methyl-
- x) Spiro[pregnane-3,2'-thiazolidine]-4'-carboxylic acid, 11 α -hydroxy-20-oxo-, sodium salt
- xi) 17 β -Dimethylamino-17-ethynyl-5 α -androstane-11 β -ol
- xii) 6 β -Hydroxy-3,5-cyclo-5 α -pregnan-20-one, nitrite
- 20 xiii) 3 α -Hydroxy-5 β -pregnane-11,20-dione, acetate, 20-O-(methylsulfonyl)-oxime
- xiv) 17 α -Methyl-5 α -androstane-11 β ,17-diol
- xv) 5 β -Pregnane-3,11,20-trione, trioxime
- xvi) 3 α -Hydroxy-5 β -pregnane-11,20-dione, 20-hydazone with hydrazide of 1-(carboxymethyl) pyridinium chloride.
- 25 A possible use of a VDRRg antagonist, could be a synergistic co-administration of the VDRRg antagonist together with other drugs such as, but not limited to, HIV protease inhibitors and cyclosporin to inhibit the expression of CYP3A4 and thus increase the bioavailability of drugs with poor pharmacokinetics due to CYP3A4 metabolism.
- Genes coding for polypeptides, such as human vitamin D receptor related gamma
- 30 (hVDRRg), may be cloned by incorporating a DNA fragment coding for the polypeptide into a recombinant DNA vehicle, e.g. a vector, and transforming suitable prokaryotic or

eukaryotic host cells. Such recombinant DNA techniques are well known and e.g. described in Methods in Enzymology, Academic Press, San Diego, CA, USA (1994), vols. 65 and 68 (1979), and vols. 100 and 101 (1983).

The host cells for use in the present invention can be prokaryotic or eukaryotic, preferably eukaryotic cells. Suitable eukaryotic host cells include but are not limited to cells from yeast, e.g. Saccharomyces, insect cells and mammalian cells such as Chinese Hamster Ovary (CHO), Baby Hamster Kidney (BHK), COS and the like. Suitable prokaryotic host cells include but are not limited to cells from Enterobacteriaceae, e.g. E. coli, Bacillus and Streptomyces.

10

EXAMPLES

The following Examples are provided for purposes of illustration only and are not to be construed as in any way limiting the scope of the present invention, which is defined by the appended claims.

15

EXAMPLE 1

Identification and isolation of human VDRRg cDNA

Expressed Sequence Tag (EST) databases were screened for nuclear receptor related sequences with a DNA-binding domain (DBD) profile of nuclear receptors. This search profile was created by multiple alignment of a selected set of nuclear receptor sub-domains followed by a statistical calculation to obtain a so called Hidden Markov Model (HMM) of different subfamily members of the nuclear receptor supergene family. The cDNA of one of the nuclear receptor related EST sequences identified (Incyte clone no 2211526) was analyzed in detail by sequencing. After DNA sequencing of the entire Incyte cDNA clone (approximately 2200 basepairs) the clone was found to encode a putative ligand-binding domain (LBD) with 54% and 44% similarity to xONR-1 and to the vitamin D receptor (VDR), respectively. The cDNA of the Incyte clone was not full-length and did not encode a sequence corresponding to a complete DBD.

20
25
30

5'-RACE (rapid amplification of cDNA ends) of random primed cDNA from human liver RNA (InVitrogen) followed by cloning and DNA sequencing showed that the 5'-part of the cDNA corresponding to the Incyte clone encoded a DBD characteristic for nuclear receptors and with 71% and 65% sequence similarity to xONR-1 and VDR, respectively.

- 5 Multiple alignments in combination with evolutionary neighbor-joining tree analysis placed the polypeptide encoded by the cDNA (specified in Fig. 1) in the group of VDRs (Figs. 2 and 3) and was named human vitamin D receptor related gamma (VDRRg). The deduced amino acid sequence of VDRRg is given in Fig. 4.

10 EXAMPLE 2

Expression of VDRRg mRNA in human tissues

- Multiple tissue northern blots (Clontech) was used to determine the expression pattern of VDRRg in adult human tissues. As shown in Fig. 5, VDRRg is abundantly expressed in small intestine, mucosal lining of colon and liver but not in several other tissues
- 15 including spleen, thymus, prostate, testis, ovary, peripheral blood leukocytes, heart, brain, placenta, lung, skeletal muscle, kidney and pancreas. To investigate if VDRRg was expressed at lower levels in any of the other tissues examined, the filter was exposed for an extended time (one week as compared to overnight). Even after this prolonged exposure (data not shown), expression could still only be detected in the same tissues and not in any
- 20 of the other tissues examined. The restricted expression pattern of VDRRg suggest that this receptor is likely to have an important regulatory function in liver and intestine.

EXAMPLE 3

Transient transfections of GAL4-DBD/VDRRγ-LBD fusion protein using Vitamin D3

- 25 Transient transfections were performed to analyze if vitamin D3 activate the VDRRγ polypeptide. To this end, transient co-transfections of CV-1 cells were performed with expression plasmids encoding fusion proteins of the GAL4-DBD fused to the LBD of either the VDR or the VDRR together with a reporter-plasmid containing five GAL4 responsive elements upstream of the luciferase gene. After transfection, cells were treated with vehicle
- 30 (DMSO) alone or with vitamin D3 for 48 hours followed by harvesting of the cells and measurement of the luciferase activity in cell extracts. As shown in Fig. 6, vitamin D3 (1

μM) transactivate the GAL4-DBD/VDR-LBD but not the corresponding GAL4-DBD/-VDRRγ-LBD polypeptide under these conditions. This indicates that the two receptors may have distinct ligand-binding specificities.

5 EXAMPLE 4

Identification and isolation of human VDRRγ cDNAs encoding multiple N-terminal isoforms

5'-RACE (see Example 1) of cDNA from human liver RNA followed by cloning and DNA sequencing identified an additional human VDRRγ cDNA with alternatively spliced
10 5'-end (see Fig. 7). The VDRRγ cDNAs are thus able to encode at least one alternative N-terminal variant (Fig. 8) in addition to the VDRRγ polypeptide shown in Fig. 4. The polypeptides disclosed in Fig. 4 and Fig. 8 which correspond to the differentially spliced VDRRγ cDNAs are designated as VDRRγ-1 and VDRRγ-2, respectively.

15

EXAMPLE 5

VDRRγ heterodimerise with RXR and bind to direct repeats (DRs) spaced by three or four nucleotides

Expression plasmids containing VDRRγ or RXRβ cDNAs were transcribed using T7
20 polymerase and translated *in vitro* in TNT reticulocyte lysates (Promega, Madison, WI, USA). To investigate the DNA-binding specificity of VDRRγ a native gel mobility assay was employed essentially as described (Berkenstam et al., Cell, 69, 401-412, 1992) in which *in vitro* translated VDRRγ was incubated in the presence or absence of *in vitro* translated RXRβ with different 32P-labelled direct repeats (DR-1 to DR-5) as indicated in Fig. 9. The
25 direct repeats were derived from the DR-5 element in the RAR-β2 promoter (de Thé et al., Nature, 343, 177-180, 1990) and modified to be separated by one to five nucleotides (Pettersson et al., Mechanisms of Dev., 54, 1-13, 1995). Protein-DNA complexes were separated on native 5% polyacryl-amide/0.25xTBE gels followed by autoradiography. As shown in Fig. 9, of the five DRs tested efficient VDRRγ binding could only be detected
30 with DRs separated by three or four nucleotides and only in the presence of RXR. However, weaker RXR-dependent binding could also be observed to DR-2 and DR-1 elements. These

results demonstrate that VDRR γ require RXR heterodimerisation for efficient DNA-binding to a specific subset of DRs. These results, however, do not exclude the possibility that VDRR γ may bind as a monomer, dimer or heterodimer to distinct but related DNA-sequences. Importantly, our results demonstrate that VDRR γ and other nuclear receptors including the VDR (e.g. Markose, E. R. et al., Proc. Natl. Acad. Sci. USA, 87, 1701-1705, 1990), THR α s (e.g. Gronemeyer, H. and Moras, D., Nature, 375, 190-191, 1995), LXR α s (e.g. Willy, P. J. et al., Genes. Dev., 9, 1033-1045, 1995), have distinct but overlapping DNA-sequence and thus may regulate overlapping gene networks.

Interestingly, the most closely related nuclear receptor called ONR-1 (in Smith et al., 1994, Nucleic Acids Res., 22, pp66-71) or XOR-6 (in WO 96/22390) have been reported to "bind well to a retinoic acid response element, bRARE" (p. 11, line 30 in WO 96/22390).

However, although the novel nuclear receptor VDRR γ reported herein has 71% amino acid similarity in the DBD as compared to XOR-6 (fig 12), VDRR γ does not appear to bind to the same bRARE sequence (DR-5 in Fig. 9).

15

EXAMPLE 6

Pregnenolone derivatives as activators of VDRR γ

For identifying activators or ligands for VDRR γ , a library of substances structurally biased towards different classes of activators and ligands for nuclear receptors were tested. The activation of VDRR γ was analyzed in a reporter gene assay in transiently Caco-2 (TC7) cells (Carriere et al, 1994). In this initial screen, the synthetic substances with ability to activate VDRR γ were found to be structurally similar to pregnenolones (data not shown). Based on these results, naturally occurring pregnenolone derivatives were examined for activation of VDRR γ . The results are shown in Fig. 10. As is evident from Fig. 10, VDRR γ was activated about 5 to 12 fold by pregnenolone, 5 β -pregnane-3,20-dione, 5 β -pregnane-3 α ,20 β -diol and 3 α -hydroxy-5 β -pregnane-11,20-dione methanesulphonate. In contrast to the efficient activation observed by the 5 β -pregnane-3,20-dione, the corresponding planar steroid derivative 5 α -pregnane-3,20-dione did not activate the receptor. Other 5 β -pregnanes also activated VDRR γ efficiently as opposed to all planar pregnenolone derivatives tested, as is also evident from Fig. 10.

EXAMPLE 7

Pregnenolone 16 α -carbonitrile (PCN), dexamethasone and an antiprogesterin (RU486) as activators of VDRR γ

Further experiments were performed to find out if pregnenolone 16 α -carbonitrile (PCN), a glucocorticoid antagonist or dexamethasone are activators of VDRR γ . To this effect, Caco-2 cells were transfected as before with VDRR γ and the activation was analyzed after treatment of the cells with 10 μ M PCN or dexamethasone. The results are shown in Fig. 11. As is evident from Fig. 11, VDRR γ was not activated by these substances, indicating that VDRR γ is not the human PCN receptor. This suggestion is corroborated by the observation that also the antiprogesterin RU486 only caused a slight increase (two fold) in VDRR γ mediated reporter gene activity as is evident from Fig. 11:

Activators of XOR-6 (Fig. 3 in WO 96/22390) such as butyl 4-NH₂ Benzoate did not activate VDRR γ (data not shown) in similar reporter assays as used in WO 96/22390.

SEQUENCE LISTING

<110> Pharmacia & Upjohn AB

<120> Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof.

<130> 1788sequence listing

<140>

<141>

<150> 9703745-1

<151> 1997-10-14

<150> 9801148-9

<151> 1998-03-31

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 2910

<212> DNA

<213> Homo sapiens

<400> 1

cctctgaagg ttctagaatc gatagtgaat tcgtgggacg ggaagaggaa gcactgcctt 60
tacttcagtg ggaatctcgg cctcagcctg caagccaagt gttcacagtg aaaaaagcaa 120
gagaataagc taatactcct gtcctgaaca aggcagcggc tccttggtaa agctactcct 180
tgatcgatcc ttgcaccgg attgttcaaa gtggacccca ggggagaagt cggagcaaag 240
aacttaccac caagcagtcc aagaggccca gaagcaaacc tggaggtgag acccaaagaa 300
agctggaacc atgctgactt tgtacactgt gaggacacag agtctgttcc tggaaagccc 360
agtgtaacg cagatgagga agtcggaggt ccccaaactt gccgtgtatg tggggacaag 420
gccactggct atcacttcaa tgcattgaca tgtgaaggat gcaagggcct tttcaggagg 480
gccatgaaac gcaacgccc gctgaggtgc cccttccgga agggcgccctg cgagatcacc 540
cggaagaccc ggcgacagtg ccaggcctgc cgcctgcgca agtgcctgga gagcggcatg 600
aagaaggaga tgatcatgtc cgacgaggcc gtggaggaga ggcgggcctt gatcaagcgg 660
aagaaaagtg aacggacagg gactcagcca ctgggagtgc aggggctgac agaggagcag 720
cggatgatga tcaggagct gatggacgt cagatgaaa cctttgacac taccttctcc 780
catttcaaga atttccggt gccagggtg cttagcagtg gctgcgagtt gccagagtct 840
ctgcaggccc catcgaggga agaagctgcc aagtggagcc aggtccgga agatctgtgc 900
tcttgaagg tctctctgca gctgcggggg gaggatggca gtgtctggaa ctacaaaccc 960
ccagccgaca gtggcgggaa agagatctt tcctgctgc cccacatggc tgacatgtca 1020
acctacatgt tcaaaggcat catcagctt gccaaagtca tctctactt cagggacttg 1080

SUBSTITUTE SHEET (RULE 26)

ccccgcgagg accagatcic cctgctgaag ggggccgctt tcgagctgtg tcaactgaga 1140
ttcaacacag tgttcaacgc ggagactgga acctgggagt gggccggct gtcctactgc 1200
ttggaagaca ctgcaggtgg ctccagcaa ctctactgg agcccatgct gaaattccac 1260
tacatgctga agaagctgca gctgcatgag gaggagtatg tgctgatgca ggccatctcc 1320
ctctctccc cagaccgccc aggtgtgctg cagcaccgcg tgggtggacca gctgcaggag 1380
caattcgcca ttactctgaa gtcctacatt gaatgcaatc ggccccagcc tgctcatagg 1440
ttctgttcc gtgaagatca tggctatgct caccgagctc cgcagcatca atgctcagca 1500
caccagcgg ctgctgcgca tcaggacat acaccccttt gctacgccc tcatgcagga 1560
gttgttcggc atcacaggta gctgagcggc tgcccttggg tgacacctcc gagaggcagc 1620
cagaccaga gccctctgag ccgccactcc cgggccaaga cagatggaca ctgccaagag 1680
ccgacaatgc cctgctggcc tgtctcccta gggaattcct gctatgacag ctggctagca 1740
ttctcagga aggacatggg tgccccccac cccagttca gctgtaggg agtgaagcca 1800
cagactctta cgtggagagt gcactgacct gtaggtcagg accatcagag aggcaaggtt 1860
gccctttcct tttaaaaggc cctgtggtct ggggagaaat ccctcagatc ccactaaagt 1920
gtcaaggtgt ggaagggacc aagcgacaa ggataggcca tctggggctct atgccacat 1980
accacgttt gtctgcttcc tgagtctttt catgctacc tctaatagtc ctgtctccca 2040
cttcccacic gttcccctcc tctccgagc tgetttgtgg gtcaaggcc tgtactcacc 2100
ggcagggtgca tgagtatctg tgggagtcct cttagagatg gagaagccag gaggcctgca 2160
ccaaatgtca gaagcttggc atgacctcat tccggccaca tcattctgtg tctctgcatc 2220
cattgaaca cattattaag cactgataat aggtagcctg ctgtggggta tacagcattg 2280
actcagatat agatcctgag ctacagagt ttatagttaa aaaaacaaac agaaacacaa 2340
acaatttga tcaaaaggag aaaatgataa gtgacaaaag cagcacaagg aatttcctg 2400
tgtggatgct gagctgtgat ggcaggcact gggtaaccaa gtgaagggtc ccgaggacat 2460
gagctcttag gagcaagggc acaaaactgca gctgtgagtg cgtgtgtgtg atttgggtga 2520
ggtaggtctg ttgccactt gatggggcct gggttgttc ctggggctgg aatgctgggt 2580
atgctctgtg acaaggctac gctgacaatc agttaaacac accggagaag aaccatttac 2640
atgcacctta tatttctgtg tacacatcta ttctcaaagc taaagggtat gaaagtcct 2700
gccttgttta tagccacttg tgagtaaaaa ttttttga tttcacaaa ttacttta 2760
tataaggcat tccacaccta agaactagt ttgggaaatg tagccctggg tttaatgtca 2820
aatcaaggca aaaggaatta aataatgtac ttttgctaa aaaaaaaaaa aaaaaaaaaa 2880
aaaaaaaaa aaaaaaaaaa aaaaaagcnt 2910

<210> 2

<211> 437

<212> PRT

<213> Homo sapiens

<400> 2

Met Glu Val Arg Pro Lys Glu Ser Trp Asn His Ala Asp Phe Val His

1 5 10 15

Cys Glu Asp Thr Glu Ser Val Pro Gly Lys Pro Ser Val Asn Ala Asp

20 25 30

Glu Glu Val Gly Gly Pro Gln Ile Cys Arg Val Cys Gly Asp Lys Ala

35 40 45

Thr Gly Tyr His Phe Asn Val Met Thr Cys Glu Gly Cys Lys Gly Phe

50 55 60

Phe Arg Arg Ala Met Lys Arg Asn Ala Arg Leu Arg Cys Pro Phe Arg

65 70 75 80

Lys Gly Ala Cys Glu Ile Thr Arg Lys Thr Arg Arg Gln Cys Gln Ala

85 90 95

Cys Arg Leu Arg Lys Cys Leu Glu Ser Gly Met Lys Lys Glu Met Ile

100 105 110

Met Ser Asp Glu Ala Val Glu Glu Arg Arg Ala Leu Ile Lys Arg Lys

115 120 125

Lys Ser Glu Arg Thr Gly Thr Gln Pro Leu Gly Val Gln Gly Leu Thr

130 135 140

Glu Glu Gln Arg Met Met Ile Arg Glu Leu Met Asp Ala Gln Met Lys

145 150 155 160

Thr Phe Asp Thr Thr Phe Ser His Phe Lys Asn Phe Arg Leu Pro Gly

165 170 175

Val Leu Ser Ser Gly Cys Glu Leu Pro Glu Ser Leu Gln Ala Pro Ser

180 185 190

Arg Glu Glu Ala Ala Lys Trp Ser Gln Val Arg Lys Asp Leu Cys Ser

SUBSTITUTE SHEET (RULE 26)

195 200 205
Leu Lys Val Ser Leu Gln Leu Arg Gly Glu Asp Gly Ser Val Trp Asn
210 215 220
Tyr Lys Pro Pro Ala Asp Ser Gly Gly Lys Glu Ile Phe Ser Leu Leu
225 230 235 240
Pro His Met Ala Asp Met Ser Thr Tyr Met Phe Lys Gly Ile Ile Ser
245 250 255
Phe Ala Lys Val Ile Ser Tyr Phe Arg Asp Leu Pro Ile Glu Asp Gln
260 265 270
Ile Ser Leu Leu Lys Gly Ala Ala Phe Glu Leu Cys Gln Leu Arg Phe
275 280 285
Asn Thr Val Phe Asn Ala Glu Thr Gly Thr Trp Glu Cys Gly Arg Leu
290 295 300
Ser Tyr Cys Leu Glu Asp Thr Ala Gly Gly Phe Gln Gln Leu Leu Leu
305 310 315 320
Glu Pro Met Leu Lys Phe His Tyr Met Leu Lys Lys Leu Gln Leu His
325 330 335
Glu Glu Glu Tyr Val Leu Met Gln Ala Ile Ser Leu Phe Ser Pro Asp
340 345 350
Arg Pro Gly Val Leu Gln His Arg Val Val Asp Gln Leu Gln Glu Gln
355 360 365
Phe Ala Ile Thr Leu Lys Ser Tyr Ile Glu Cys Asn Arg Pro Gln Pro
370 375 380
Ala His Arg Phe Leu Phe Leu Lys Ile Met Ala Met Leu Thr Glu Leu
385 390 395 400
Arg Ser Ile Asn Ala Gln His Thr Gln Arg Leu Leu Arg Ile Gln Asp
405 410 415
Ile His Pro Phe Ala Thr Pro Leu Met Gln Glu Leu Phe Gly Ile Thr
420 425 430
Gly Ser Phe Ile Gly
435

SUBSTITUTE SHEET (RULE 26)

<210> 3

<211> 2802

<212> DNA

<213> Homo sapiens

<400> 3

tgaattcgtg ggcctgctgg gttagtctg gcagcccc tgaggccaag gacagcagca 60
tgacagtcac caggactcac cactcaagg aggggtccct cagagcacct gccatacccc 120
tgcacagtgc tgcggctgag ttggcttcaa accatccaag aggcccagaa gcaaacctgg 180
aggtagagacc caaagaaagc tggaacctg ctgactttgt aactgtgag gacacagagt 240
ctgttctctg aaagcccagt gtcaacgcag atgaggaagt cggaggtccc caaatctgcc 300
gtgtatgtgg ggacaaggcc actggctatc acttcaatgt catgacatgt gaaggatgca 360
agggctttt caggagggcc atgaaacgca acgcccggct gaggtgcccc tccggaagg 420
gcgctgcga gatcaccggg aagaccggc gacagtgcc ggctgccc ctgcgcaagt 480
gcctggagag cggcatgaag aaggagaiga tcatgtccga cgaggccgtg gaggagaggc 540
gggcttgat caagcggaag aaaagtgaac ggacaggac tcagccactg ggagtgcagg 600
ggctgacaga ggagcagcgg atgatgatca gggagctgat ggacgctcag atgaaaacct 660
ttgacactac ctctcccat ttcaagaatt tccggctgcc aggggtgctt agcagtggct 720
gcgagtggc agagtctctg caggcccat cgagggaaga agctgccaag tggagccagg 780
tccggaaga tctgtgctt ttgaaggtct ctctgcagct gcggggggag gatggcagt 840
tctggaacta caaacccca gccgacagt gcgggaaaga gatcttctcc ctgctgcccc 900
acatggctga catgtcaacc tacatgttca aaggcatcat cagcttgcc aaagtcatt 960
cctacttcag ggacttgccc atcaggacc agatctccct gctgaagggg gccgctttcg 1020
agctgtgtca actgagattc aacacagtgt tcaacgcgga gactggaacc tgggagtgtg 1080
gccggctgtc ctactgctg gaagacactg caggtggctt ccagcaactt ctactggagc 1140
ccatgtgaa attccactac atgtgaaga agctgcagct gcatgaggag gattatgtgc 1200
tgatgcaggc catctccctc ttctcccag accgcccagg tgtgtgcag caccgcgtgg 1260
tggaccagct gcaggagcaa ttgccatta ctctgaagtc ctacattgaa tgcaatcggc 1320
cccagcctgc tcataggctc ttgttctga agatcatggc tatgctcacc gagctccgca 1380
gcatcaatgc tcagcacacc cagcggctgc tgcgcatcca ggacatacac cctttgcta 1440

SUBSTITUTE SHEET (RULE 26)

cgccccat gcaggagtgc ttcggcatca caggtagctg agcggctgcc cttgggtgac 1500
 acctccgaga ggcagccaga cccagagccc tctgagccgc cactcccgagg ccaagacaga 1560
 tggacactgc caagagccga caatgccctg ctggcctgct tccctaggga attctgcta 1620
 tgacagctgg ctagcattcc tcaggaagga catgggtgcc cccaccccc agttcagtct 1680
 gtagggagtgc aagccacaga ctctacgtg gagagtgcac tgacctgtag gtcaggacca 1740
 tcagagagggc aaggttgccc ttctcttta aaaggccctg tggctgggg agaaatccct 1800
 cagatccac taaagtgtca aggtgtggaa gggaccaagc gaccaaggat aggccatctg 1860
 gggctatgc ccacataccc acgtttgttc gcttctgag tctttcatt gctacctta 1920
 atagtctgt ctccacttc ccactgttc cctcctctt ccgagctgct ttgtgggctc 1980
 aaggcctgta ctcatggca ggtgcatgag tatctgtggg agtcctctag agagatgaga 2040
 agccaggagg cctgcaccaa atgtcagaag cttggcatga cctcattccg gccacatcat 2100
 tctgtgtctc tgcattcatt tgaacacatt attaaagcact gataataggt agcctgctgt 2160
 ggggtataca gcattgactc agatatagat cctgagctca cagagttat agttaaaaa 2220
 acaaacagaa acacaaacaa ttggatcaa aaggagaaaa tgataagtga caaagcagc 2280
 acaaggaatt tccctgtgtg gatgctgagc tgtgatggca ggcactgggt acccaagtga 2340
 aggttccga ggacatgagt ctgtaggagc aagggcacaa actgcagctg tgagtgcgtg 2400
 tgtgtgattt ggtgtaggta ggtctgttg ccactgatg gggcctgggt ttgttctgg 2460
 ggctggaatg ctgggtatgc tctgtgacaa ggctacgtg acaatcagti aaacacaccg 2520
 gagaagaacc atttatgc accttatatt tctgtgtaca catctattct caaagctaaa 2580
 gggatgaaa gtgcctgcct tgtttatagc cactgtgag taaaaattt ttgcattt 2640
 cacaaattat accttatata aggcattcca cacctaagaa ctagttttgg gaaatgtagc 2700
 cctgggttta atgtcaaatc aaggcaaaag gaattaaata atgtactttt ggctaaaaa 2760
 aaaaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaaaa aa 2802

<210> 4

<211> 473

<212> PRT

<213> Homo sapiens

<400> 4

Met Thr Val Thr Arg Thr His His Phe Lys Glu Gly Ser Leu Arg Ala

1	5	10	15
---	---	----	----

Pro Ala Ile Pro Leu His Ser Ala Ala Ala Glu Leu Ala Ser Asn His
20 25 30

Pro Arg Gly Pro Glu Ala Asn Leu Glu Val Arg Pro Lys Glu Ser Trp
35 40 45

Asn His Ala Asp Phe Val His Cys Glu Asp Thr Glu Ser Val Pro Gly
50 55 60

Lys Pro Ser Val Asn Ala Asp Glu Glu Val Gly Gly Pro Gln Ile Cys
65 70 75 80

Arg Val Cys Gly Asp Lys Ala Thr Gly Tyr His Phe Asn Val Met Thr
85 90 95

Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ala Met Lys Arg Asn Ala
100 105 110

Arg Leu Arg Cys Pro Phe Arg Lys Gly Ala Cys Glu Ile Thr Arg Lys
115 120 125

Thr Arg Arg Gln Cys Gln Ala Cys Arg Leu Arg Lys Cys Leu Glu Ser
130 135 140

Gly Met Lys Lys Glu Met Ile Met Ser Asp Glu Ala Val Glu Glu Arg
145 150 155 160

Arg Ala Leu Ile Lys Arg Lys Lys Ser Glu Arg Thr Gly Thr Gln Pro
165 170 175

Leu Gly Val Gln Gly Leu Thr Glu Glu Gln Arg Met Met Ile Arg Glu
180 185 190

Leu Met Asp Ala Gln Met Lys Thr Phe Asp Thr Thr Phe Ser His Phe
195 200 205

Lys Asn Phe Arg Leu Pro Gly Val Leu Ser Ser Gly Cys Glu Leu Pro
210 215 220

Glu Ser Leu Gln Ala Pro Ser Arg Glu Glu Ala Ala Lys Trp Ser Gln
225 230 235 240

Val Arg Lys Asp Leu Cys Ser Leu Lys Val Ser Leu Gln Leu Arg Gly
245 250 255

Glu Asp Gly Ser Val Trp Asn Tyr Lys Pro Pro Ala Asp Ser Gly Gly
260 265 270

SUBSTITUTE SHEET (RULE 26)

Lys Glu Ile Phe Ser Leu Leu Pro His Met Ala Asp Met Ser Thr Tyr
275 280 285

Met Phe Lys Gly Ile Ile Ser Phe Ala Lys Val Ile Ser Tyr Phe Arg
290 295 300

Asp Leu Pro Ile Glu Asp Gln Ile Ser Leu Leu Lys Gly Ala Ala Phe
305 310 315 320

Glu Leu Cys Gln Leu Arg Phe Asn Thr Val Phe Asn Ala Glu Thr Gly
325 330 335

Thr Trp Glu Cys Gly Arg Leu Ser Tyr Cys Leu Glu Asp Thr Ala Gly
340 345 350

Gly Phe Gln Gln Leu Leu Leu Glu Pro Met Leu Lys Phe His Tyr Met
355 360 365

Leu Lys Lys Leu Gln Leu His Glu Glu Glu Tyr Val Leu Met Gln Ala
370 375 380

Ile Ser Leu Phe Ser Pro Asp Arg Pro Gly Val Leu Gln His Arg Val
385 390 395 400

Val Asp Gln Leu Gln Glu Gln Phe Ala Ile Thr Leu Lys Ser Tyr Ile
405 410 415

Glu Cys Asn Arg Pro Gln Pro Ala His Arg Phe Leu Phe Leu Lys Ile
420 425 430

Met Ala Met Leu Thr Glu Leu Arg Ser Ile Asn Ala Gln His Thr Gln
435 440 445

Arg Leu Leu Arg Ile Gln Asp Ile His Pro Phe Ala Thr Pro Leu Met
450 455 460

Gln Glu Leu Phe Gly Ile Thr Gly Ser
465 470

CLAIMS

1. A mammalian, preferably human, isolated or recombinant nucleic acid comprising a contiguous nucleic acid sequence encoding a vitamin D receptor related (VDRR) polypeptide.
2. An isolated or recombinant DNA/nucleic acid according to Fig. 1 or Fig. 7 or alleles thereof encoding a new VDRR polypeptide.
3. The nucleic acid according to claim 1 or claim 2 encoding the VDRR polypeptide containing a DNA-binding domain (DBD) comprising about 77 amino acids with 9 cysteine residues,, wherein said DBD is characterized by the following amino acid sequence similarity:
 - (i) at least 60% amino acid sequence similarity with the DBD of hVDR; and
 - (ii) at least 65% amino acid sequence similarity with the DBD of xONR1.
4. The nucleic acid according to claim 3, wherein said DBD is characterized by the following amino acid sequence similarity:
 - (i) about 65% amino acid sequence similarity with the DBD of hVDR; and
 - (ii) about 71% amino acid sequence similarity with the DBD of xONR1.
5. The nucleic acid according to any previous claim, encoding the VDRR polypeptide, wherein the ligand-binding domain (LBD) of said polypeptide is characterized by the following amino acid sequence similarity, relative to the LBDs of hVDR and xONR1, respectively:
 - (i) at least about 30% amino acid sequence similarity with the LBD of hVDR; and
 - (ii) at least about 40% amino acid sequence similarity with the LBD of xONR1.

6. The nucleic acid according to claim 5, wherein said LBD is characterized by the following amino acid sequence similarity:
 - (i) at least 35% amino acid sequence similarity with the LBD of hVDR; and
 - (ii) at least 45% amino acid sequence similarity with the LBD of xONR1.
7. The nucleic acid according to claim 6, wherein said LBD is characterized by the following amino acid sequence similarity:
 - (i) about 42% amino acid sequence similarity with the LBD of hVDR; and
 - (ii) about 54% amino acid sequence similarity with the LBD of xONR1.
8. The nucleic acid according to any previous claim, wherein said nucleic acid sequence is that given in Fig. 1 or Fig. 7 or alleles thereof.
9. The nucleic acid according to claim 8, wherein said nucleic acid sequence is the same or substantially the same as given in Fig. 1 or Fig. 7.
10. A nucleic acid probe for the detection of a nucleic acid sequence encoding a VDRR polypeptide in a sample.
11. The nucleic acid probe according to claim 10, wherein said probe comprises at least 14 contiguous nucleotides of the nucleic acid sequence given in Fig. 1 or Fig. 7.
12. A method for identifying clones encoding a VDRR polypeptide said method comprising screening a genomic or cDNA library with a nucleic acid probe according to claims 10 or 11 under low stringency hybridization conditions, and identifying those clones which display a substantial degree of hybridization to said probe.
13. An expression vector comprising a nucleic acid according to any of claims 1 -9.

14. A cell containing a nucleic acid according to any of claims 1 -9.
15. A cell containing an expression vector according to claim 14.
16. A process for recombinant production of a VDRR polypeptide, said process comprising expressing the nucleic acid of claims 1 to 9 in a suitable host cell.
17. The process according to claim 16, wherein the host cell is eukaryotic.
18. An isolated or recombinant mammalian, preferably human, VDRR polypeptide.
19. The isolated or recombinant VDRR polypeptide according to claim 18 comprising the amino acid sequence substantially the same or the same as given in Fig. 4 or Fig. 8.
20. A method to produce specific monoclonal and polyclonal antibodies to the polypeptide according to any of claims 18 and 19 comprising the injection of the protein to a mammalian.
21. A pharmaceutical formulation comprising an isolated or recombinant VDRR polypeptide according to claims 18 or 19, and one or more therapeutically acceptable excipients.
22. A method for identifying a ligand to a VDRR, by a cell-based reporter assay, transgenic-animal reporter assay or *in vitro*-binding assay.
23. A method for identifying a substance for treatment of a condition affected by a VDRR polypeptide, comprising screening for an agonist or an antagonist of VDRR polypeptide signal transduction to be used for treating metabolic, proliferative or inflammatory conditions.

24. A mammalian, preferably human, VDRR polypeptide according to any of claims 18 and 19 for use as a medicament.
25. Use of a substance affecting VDRR signal transduction, such as an agonist or an antagonist of VDRR polypeptide signal transduction, for the manufacture of a medicament for treating metabolic, proliferative or inflammatory conditions.
26. Use according to claim 25 of a substance affecting VDRR signal transduction for the manufacture of a medicament for treating obesity, diabetes, anorexia, lipoprotein defects, hyperlipidemia, hypercholesteremia or hyperlipoproteinemia.
27. Use of a substance affecting VDRR signal transduction for the manufacture of a medicament for treating osteoporosis, rheumatoid arthritis, benign and malignant tumors, hyperproliferative skin disorders or hyperparathyroidism.
28. Use according to any of claims 25-27, wherein the substance affecting VDRR signal transduction is a chemical molecule of natural or synthetic origin with a molecular weight in the range of from about 100 up to about 500 Da, preferably with a molecular weight of about 300 Da.
29. A method for treating metabolic, proliferative or inflammatory conditions comprising introducing into a mammal a nucleic acid vector according to claim 13 encoding for expression of a VDRR polypeptide and wherein said nucleic acid vector is capable of transforming a cell *in vivo* and expressing said polypeptide in said transformed cell.
30. A method for treatment of a metabolic, proliferative or inflammatory condition by administration of a therapeutically effective amount of a substance affecting VDRR signal transduction.

31. The method according to claim 30, wherein the substance affecting VDRR signal transduction is a chemical molecule of natural or synthetic origin with a molecular weight in the range of from about 100 up to about 500 Da, preferably with a molecular weight of about 300 Da.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01548

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/72, C12N 15/10, A61K 38/17
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, C12N, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9622390 A1 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES), 25 July 1996 (25.07.96), the claims, seq. 1	1-19, 21-22, 24-27
A	--	20, 23
X	WO 9317041 A1 (THE GENERAL HOSPITAL CORPORATION), 2 Sept 1993 (02.09.93), the claims, seq. ID No 1	1-27
X	WO 9636230 A1 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES), 21 November 1996 (21.11.96)	1-27

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search	Date of mailing of the international search report
15 December 1998	21-12-1998
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer Patrick Andersson Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01548

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9306215 A1 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES), 1 April 1993 (01.04.93) --	1-19,21-22
X	Nucleic Acids Research, Volume 22, No 1, 1994, Darrin P. Smith et al, "A novel nuclear receptor superfamily member in Xenopus that associates with RXR, and shares extensive sequence similarity to the mammalian vitamin D3 receptor" page 66 - page 71 --	1-19
X	WO 8909223 A1 (ARCH DEVELOPMENT CORPORATION), 5 October 1989 (05.10.89), figure 5 --	1-19,21-22
P,X	EMBL, Databas Genbank/DBJ, accession no. AF031814, Klierer S.A. et al: "An orphan Nuclear Receptor Activated by Pregnanes Defines a Novel"; & Steroid Signaling Pathway, Cell 92:73-82(1998), 1-1709 -- -----	1-27

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE98/01548

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 28-30
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

INTERNATIONAL SEARCH REPORT
Information on patent family members

01/12/98

International application No.
PCT/SE 98/01548

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9622390 A1	25/07/96	AU 4693496 A CA 2210679 A EP 0822991 A	07/08/96 25/07/96 11/02/98
WO 9317041 A1	02/09/93	AT 172247 T AU 684458 B AU 3728393 A CA 2117491 A DE 69321580 D EP 0628054 A,B JP 7504416 T US 5686574 A US 5710017 A US 5756448 A	15/10/98 18/12/97 13/09/93 02/09/93 00/00/00 14/12/94 18/05/95 11/11/97 20/01/98 26/05/98
WO 9636230 A1	21/11/96	AU 5426596 A	29/11/96
WO 9306215 A1	01/04/93	AU 2579692 A CA 2115452 A EP 0609240 A US 5571696 A US 5696233 A US 5710004 A	27/04/93 01/04/93 10/08/94 05/11/96 09/12/97 20/01/98
WO 8909223 A1	05/10/89	EP 0407462 A JP 3504438 T US 5614620 A	16/01/91 03/10/91 25/03/97

Form PCT/ISA/210 (patent family annex) (July 1992)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/72, C12N 15/10, A61K 38/17		A1	(11) International Publication Number: WO 99/19354
			(43) International Publication Date: 22 April 1999 (22.04.99)
(21) International Application Number: PCT/SE98/01548 (22) International Filing Date: 31 August 1998 (31.08.98) (30) Priority Data: 9703745-1 14 October 1997 (14.10.97) SE 9801148-9 31 March 1998 (31.03.98) SE (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN AB [SE/SE]; S-112 87 Stockholm (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): BERKENSTAM, Anders [SE/SE]; Långholmsgatan 11, S-117 33 Stockholm (SE). DAHLBERG, Mats [SE/SE]; Sankt Göransgatan 64, S-112 87 Stockholm (SE). (74) Agents: TANNERFELDT, Agneta et al.; Pharmacia & Upjohn AB, S-112 87 Stockholm (SE).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: NOVEL VITAMIN D RECEPTOR RELATED POLYPEPTIDES, NUCLEIC ACID SEQUENCE ENCODING THE SAME AND USES THEREOF			
(57) Abstract			
<p>The present invention relates to novel vitamin D receptor related (VDRR) polypeptides, and formulations containing the same. Nucleic acid sequences encoding the VDRR polypeptides, expression vectors containing such sequences and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel VDRR polypeptides of the invention. The invention further relates to VDRR polypeptides for use as medicaments, and use of substances affecting VDRR signal transduction for the manufacture of medicaments for treating metabolic, proliferative or inflammatory conditions. The present invention also relates to methods for identifying clones encoding a VDRR polypeptide, methods for identifying ligands to a VDRR and methods for identifying substances for treatment of conditions affected by a VDRR polypeptide. More specifically, the novel VDRR polypeptide can be the polypeptide designated VDRRγ, which may be regulated by any small chemical molecule similar in structure to known ligands for nuclear receptors.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL VITAMIN D RECEPTOR RELATED POLYPEPTIDES. NUCLEIC ACID
SEQUENCE ENCODING THE SAME AND USES THEREOF

5 FIELD OF THE INVENTION

The present invention relates to novel vitamin D receptor related (VDRR) poly-
peptides. Nucleic acid sequences encoding the same, expression vectors containing such
sequences and host cells transformed with such expression vectors are also disclosed, as are
10 methods for the expression of the novel VDRR polypeptides of the invention, and uses
thereof.

BACKGROUND OF THE INVENTION

15 Nuclear hormone receptors is a large group of conditionally regulated transcription
factors. These receptors are activated and regulate target gene expression in response to
binding a variety of small chemical molecules (ligands) including steroids, vitamin D3,
retinoids, eicosanoides (prostanoids), thyroid hormone and cholesterol derivatives.

A growing number of structurally related receptors have been identified for which no
20 ligands yet have been identified. This group of receptors is referred to as orphan nuclear
receptors (ONRs). A review of the ONRs can be found in Enmark et al, Mol. Endo., vol. 10,
No. 11 (1996) pp. 1293-1307, which is hereby incorporated by reference. The pivotal
importance of a number of ONRs for processes such as metabolic homeostasis, cell
differentiation and development have been demonstrated both by biochemical and genetic
25 techniques. In addition, several ONRs have also been implicated as key factors in a variety
of common diseases and disorders such as diabetes, obesity, inflammatory conditions and
proliferative diseases.

Based on these findings it is generally believed that novel ONRs are going to become
potential drug targets for therapeutic invention of common diseases. Thus, it is of great
30 importance to identify such receptors.

SUMMARY OF THE INVENTION

The present invention relates to novel vitamin D receptor related (VDRR) polypeptides, and formulations containing the same. Nucleic acid sequences encoding the VDRR polypeptides, expression vectors containing such sequences and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel VDRR polypeptides of the invention. The invention further relates to VDRR polypeptides for use as medicaments, and use of substances affecting VDRR signal transduction for the manufacture of medicaments for treating metabolic, proliferative or inflammatory conditions. The present invention also relates to methods for identifying clones encoding a VDRR polypeptide, methods for identifying ligands to a VDRR and methods for identifying substances for treatment of conditions affected by a VDRR polypeptide. More specifically, the novel VDRR polypeptide can be the polypeptide designated VDRR γ , which may be regulated by any small chemical molecule similar in structure to known ligands for nuclear receptors.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 - The cDNA sequence encoding the novel nuclear receptor polypeptide vitamin D receptor related gamma (VDRRg) is shown.

Figure 2 - Evolutionary neighbor-joining tree for VDRRg as given by DBD-HMM alignment.

Figure 3 - Evolutionary neighbor-joining tree for VDRRg as given by LBD-HMM alignment.

Figure 4 - The deduced amino acid sequence of VDRRg is shown.

Figure 5 - Expression of VDRRg in adult human tissues. The numbers on the right hand side, refer to kilobasepairs of the mRNA.

Figure 6 - Vitamin D3 transactivate a GAL4-DBD/VDR-LBD fusion protein but not a GAL4-DBD/VDRR γ -LBD fusion protein in transient transfections of CV-1 cells. The number on the left hand side refer to relative luciferase activity of the GAL4-luciferase reporter gene.

Figure 7 - The cDNA sequence encoding VDRRg-2 with an alternatively spliced 5'-end compared to VDRRg is shown.

Figure 8 - The deduced amino acid sequence of VDRRg-2 is shown.

Figure 9 - Heterodimerization of VDRRg with a retinoid X receptor (RXR) is shown.

5 Figure 10 - The effect of pregnenolone derivatives as activators of VDRRg are shown.

Figure 11 - The effect of pregnenolone 16 α -carbonitrile (PCN), dexamethasone and an antiprogesterin (RU486) as activators of VDRRg are shown.

10 Figure 12 - Percent similarity between the new genes VDRRg-1 and VDRRg-2 and the known genes XOR-6, HVDR, CAR-1 and CAR-2.

Figure 13 - Percent identity between the new genes VDRRg-1 and VDRRg-2 and the known genes XOR-6, HVDR, CAR-1 and CAR-2.

15

DETAILED DESCRIPTION OF THE INVENTION

The objects above are met by the present invention, which relates to a mammalian, preferably human, isolated or recombinant nucleic acid comprising a contiguous nucleic acid
20 sequence encoding a vitamin D receptor related (VDRR) polypeptide. The VDRR polypeptide is suitably origin.

In preferred embodiments of the present invention, the nucleic acid encoding the VDRR polypeptide contains a DNA-binding domain (DBD) comprising about 77 amino acids with 9 cysteine residues. The DBD is further characterized by the following amino
25 acid sequence similarity relative to the DBDs of human Vitamin D Receptor (hVDR) and Orphan Nuclear Receptor 1 isolated from *Xenopus laevis* (xONR1 = XOR-6), respectively:

- (i) at least about 60% amino acid sequence similarity with the DBD of hVDR; and
- (ii) at least about 65% amino acid sequence similarity with the DBD of xONR1.

More particularly, the amino acid sequence similarity relative to the DBDs of hVDR and
30 xONR1, respectively is

- (i) about 65% amino acid sequence similarity with the DBD of hVDR; and

(ii) about 71% amino acid sequence similarity with the DBD of xONR1.

In preferred embodiments of the present invention, the nucleic acid encoding the VDRR polypeptide contains a ligand-binding domain (LBD) characterized by the following amino acid sequence similarity, relative to the LBDs of hVDR and xONR1, respectively:

- 5 (i) at least about 30% amino acid sequence similarity with the LBD of hVDR, suitably at least 35% amino acid sequence similarity with the LBD of hVDR; and
(ii) at least about 40% amino acid sequence similarity with the LBD of xONR1, suitably at least 45% amino acid sequence similarity with the LBD of xONR1.

More particularly, the amino acid sequence similarity relative to the LBDs of hVDR and
10 xONR1, respectively is

- (i) about 42% amino acid sequence similarity with the LBD of hVDR; and
(ii) about 54% amino acid sequence similarity with the LBD of xONR1.

“amino acid sequence similarity” refers to: $100 \times \text{Consensus Length} / (\text{Consensus Length} + \text{Mismatches} + \text{Gaps})$.

- 15 The term amino acid sequence identity can also be used. Amino acid sequence identity is calculated by comparing the absolute amino acid residue identity. In Figure 13 the amino acid sequence identity between the new genes VDRRg-1 and VDRRg-2 and the known genes are shown.

In particularly preferred embodiments, the nucleic acid sequences of the present
20 invention are substantially the same as those given in Fig. 1 or Fig. 7, the same or alleles thereof.

The present invention also relates to a nucleic acid probe for the detection of a nucleic acid sequence encoding a VDRR polypeptide in a sample. Suitably, the probe comprises at least 14 contiguous nucleotides, and preferably at least 28 contiguous nucleotides, of the nucleic acid sequences given in Fig. 1 or Fig. 7. The nucleic acid probe can be
25 used in a method for identifying clones encoding a VDRR polypeptide, wherein the method comprises screening a genomic or cDNA library with the probe under low stringency hybridization conditions, and identifying those clones which display a substantial degree of hybridization to said probe.

30 The present invention further relates to an isolated or recombinant VDRR polypeptide. The polypeptide can be full-length, at which the sequence of amino acids is identical to

the corresponding sequence found in mammals in general, and in human beings in particular. In the present invention, the polypeptide can also be a truncated, extended or mutated form of the full-length polypeptide. Truncated and extended forms relate to VDRR polypeptides where one or more amino acids are missing or have been added, respectively, at the N terminal end of the polypeptide chain. Mutated forms relate to VDRR polypeptides where one or more amino acid has been substituted by another amino acid. Suitably, the isolated or recombinant VDRR polypeptide exhibits the amino acid sequences given in Fig. 4 or Fig. 8.

The N-terminal sequence of the present nucleic acids encoding VDRR polypeptides, as well as the amino acid sequence of the present VDRR polypeptides, may vary. Thus, various N-terminal isoforms are envisaged, e.g. any of $\alpha 1$, $\alpha 2$, $\beta 1$, $\beta 2$, $\beta 3$, $\beta 4$, $\gamma 1$ or $\gamma 2$ as disclosed in Fig. 7B of Transcription Factors 3: nuclear receptors, Protein Profile, vol. 2, issue 11 (1995), pp. 1173-1235. This review of nuclear receptors generally is hereby incorporated by reference. More specifically, Vitamin D receptors and related orphans, e.g. ONR1, are discussed at p. 1191-1992.

The present invention further relates to pharmaceutical formulations comprising an isolated or recombinant VDRR polypeptide, and one or more therapeutically acceptable excipients. Examples of excipients that can be used are carbohydrates, e.g. monosaccharides, disaccharides and sugar alcohols, such as saccharose and sorbitol. Further examples include amino acids, e.g. histidine and arginine, surfactants, e.g. polyoxyethylene sorbitan fatty acid esters, inorganic salts, e.g. sodium chloride and calcium chloride, and complexing agents, e.g. EDTA and citric acid.

The present formulation can be in the form of an aqueous solution ready-for-use, or dried, particularly lyophilized. In the latter case, the formulation is reconstituted with a liquid, e.g. sterile water or saline, before use.

The present invention further relates to an expression vector comprising an isolated or recombinant nucleic acid, the nucleic acid comprising a contiguous nucleic acid sequence encoding a Vitamin D receptor related (VDRR) polypeptide. The invention also relates to a cell containing such an expression vector.

The present invention further relates to a cell containing the claimed nucleic acid, the nucleic acid comprising a contiguous nucleic acid sequence encoding a Vitamin D receptor related (VDRR) polypeptide.

The present invention further relates to a process for recombinant production of a VDRR polypeptide, by expressing the claimed isolated or recombinant contiguous nucleic acid sequence encoding a Vitamin D receptor related (VDRR) polypeptide in a suitable host cell, preferably an eukaryotic cell.

The present invention further relates to method for identifying a ligand to a VDRR, e.g. by a cell-based reporter assay, transgenic-animal reporter assay or *in vitro*-binding assay. It also relates to a method for identifying a substance for treatment of a condition affected by a VDRR polypeptide, comprising screening for an agonist or an antagonist of VDRR polypeptide signal transduction to be used for treating metabolic, proliferative or inflammatory conditions.

The present invention further relates to a VDRR polypeptide for use as a medicament, as well as use of a substance affecting VDRR signal transduction for the manufacture of a medicament for treating metabolic, proliferative or inflammatory conditions. More particularly, the present invention can be used for the manufacture of medicaments for treating obesity, diabetes, anorexia, lipoprotein defects, hyperlipidemia, hypercholesterolemia or hyperlipoproteinemia. The present invention can be used also for the manufacture of medicaments for treating osteoporosis, rheumatoid arthritis, benign and malignant tumors, hyperproliferative skin disorders or hyperparathyroidism.

The present invention further relates to a method for treating metabolic, proliferative or inflammatory conditions by introducing into a mammal a nucleic acid vector encoding for expression of a VDRR polypeptide. The nucleic acid vector is capable of transforming a cell *in vivo* and expressing said polypeptide in said transformed cell.

The present invention further relates to a method for treatment of a metabolic, proliferative or inflammatory condition by administration of a therapeutically effective amount of a substance affecting VDRR signal transduction, specifically a VDRR polypeptide.

In the present invention, the term "isolated" in connection with VDRR polypeptides or nucleic acids encoding the same, relates to nucleic acids or polypeptides that have been isolated from a natural source, e.g. the liver, small intestine or colon of a human being. The

isolated VDRR polypeptides or nucleic acids of the present invention are unique in the sense that they are not found in a pure or separated form in nature. Use of the term "isolated" indicates that a naturally occurring sequence has been removed from its normal cellular environment. Thus, the sequence may be in a cell-free environment or in a different cellular environment. The term does not imply that the sequence is the only nucleic acid or amino acid sequence present, but that it is the predominant nucleic acid or amino acid sequence present. Furthermore, the nucleic acid or polypeptide should be essentially free of non-amino acid or non-nucleic acid material naturally associated with the respective product. In this context, essentially free relates to more than 80%, suitably more than 90%, and preferably more than 95% purity.

The term "substantially the same" when referring to the nucleic acid sequences in Fig. 1 or Fig. 7 and when referring to the amino acid sequences in Fig. 4 or Fig. 8 means that they are derived from the sequences given in the figures and have the same function as those.

The inventors of the present invention, have surprisingly isolated a novel nucleic acid sequence, and a polypeptide encoded by said nucleic acid sequence. Thus, a novel cDNA encoding a polypeptide designated VDRR γ has been cloned and characterized. This polypeptide is, based on amino acid sequence similarity, a novel member of the nuclear (hormone) receptor supergene family. Hidden Markov Models (HMMs) in combination with phylogenetic analysis such as neighbor-joining tree methods and other statistical algorithms shows that VDRR γ belong to a sub-family of vitamin D receptors (VDRs) and a VDR-like receptor from *Xenopus laevis* designated xONR1 (see Smith et al., Nucl. Acids Res., 22 (1994), No. 1, pp. 66-71) or XOR-6 as in WO96/22390. The VDRR γ , therefore, is one member of a family of Vitamin D receptor related (VDRR) polypeptides.

The degree of amino acid similarity in the DBD and LBD of VDRR γ as compared to the most closely related receptors XOR-6, hVDR and CAR (see WO 93/17041) is similar to the relationship between other distinct, but related nuclear receptors. (See Fig. 12). The thyroid hormone (TRb) and retinoic acid receptor (RARb) are approximately 60% and 40% identical at the amino acid level in the DBD and LBD, respectively. By comparison, the closely related but unique genes encoding human RARa and RARb nuclear receptors are 97% and 82% identical in the DBD and LBD, respectively.

As recognized by those skilled in the art of nuclear receptors, the DBD displays the highest degree of conservation (amino acid identity) both between different nuclear receptors (paralogous) and between identical receptors from different species (orthologues). The two “zink-fingers” in the DBD are generated by two evolutionary conserved amino acid motifs

5 Cys-X2-Cys-X13-Cys-X2-Cys (amino-terminal or first zink-finger) and Cys-Xn-Cys-X9-Cys-X2-Cys (carboxy-terminal or second zink-finger) in which two pairs of cysteins chelate on zink ion. The vast majority of nuclear receptors have five amino acid residues between the first two Cys residues in the second zink-finger (Cys-X5-Cys-X9-Cys-X2-Cys) see Gronemeyer and Laudet (Protein Profile 1995, 2, issue 11) for details. The today only

10 known exception to this rule are the PPARs which have three amino acid (Cys-X3-Cys-X9-Cys-X2-Cys) residues and the TLL group of receptors which have seven (Cys-X7-Cys-X9-Cys-X2-Cys). Thus another feature which is characteristic of the novel VDRRg polypeptide described herein is that the number of amino acid residues in this part of the DBD is six (Cys-X6-Cys-X9-Cys-X2-Cys) as shown in Figs.4 and 8. Today, the only other nuclear

15 receptor like sequences found in the TREMBLE data base with the same number of amino acid residues between the two cys residues are two sequences (Q20097 and Q18155) from the worm *C. elegans* (Q20097 and Q18155). However, the entire DBD of these putative *C. elegans* nuclear receptors are only distantly related to the DBD of VDRRg. Taken together, the comparison of the DBD and LBD of the nuclear receptor VDRRg described herein (See

20 Fig.12), clearly demonstrate that this receptor is a novel member of the nuclear receptor super-gene family which is distinct from other known nuclear receptors that are most closely related to the VDRRg including ONR-1 (in Smith et al., 1994, Nucleic Acids Res., 22, pp66-71) or XOR-6 (in WO 96/22390), hVDR and CAR (WO 93/17041).

This finding, in combination with the highly restricted expression pattern we observe for

25 human VDRRγ (liver, small intestine and mucosa of colon) and in analogy to other nuclear receptors exhibiting a tissue specific expression pattern such as the peroxisome proliferator-activated receptors (PPARs) - suggest that VDRRγ performs important physiological functions in liver, small intestine and colon. Accordingly, VDRRγ is likely to be an important sensor of key metabolic pathways affecting lipid, carbohydrate or amino acid

30 metabolism/homeostasis. In addition, the highly selective tissue specific expression pattern

suggest that VDRR γ may participate in cellular differentiation and development of these tissues.

An additional human VDRR γ cDNA with an alternatively spliced 5'-end has been identified (see Fig. 7). The VDRR γ cDNAs are thus able to encode at least one alternative
5 N-terminal variant (Fig. 8) in addition to the VDRR γ polypeptide shown in Fig. 4. In analogy to other members of the nuclear receptor supergene family such as ROR α and RAR α these N-terminal isoforms of VDRR γ may specify different functions including DNA-binding specificity and/or promoter specific activation (Gronemeyer and Laudet, 1995).

10 In the present specification, the term VDRR γ relates to the various polypeptides corresponding to the differentially spliced VDRR γ cDNAs including VDRR γ -1 and VDRR γ -2. However, when reference is made to Fig. 1 and Fig. 4, VDRR γ cDNA and VDRR γ relates specifically to VDRR γ -1 cDNA and VDRR γ -1, respectively. In the same way, when reference is made to Fig. 7 and Fig. 8, VDRR γ cDNA and VDRR γ relates
15 specifically to VDRR γ -2 cDNA and VDRR γ -2, respectively.

In contrast to the VDRR γ -2 cDNA, the VDRR γ -1 cDNA does not contain a classical AUG initiation codon but instead may initiate at an alternative CUG codon. This putative non-AUG start site is located in a favorable sequence context for efficient initiation from alternative start sites and is in frame with the entire open reading frame and preceded by a
20 stop codon.

Taken together, the VDRRs in general, and more specifically the VDRR γ , may be important in

- 1) metabolic diseases such as obesity, diabetes (type I and II), lipoprotein disorders,
- 2) proliferative conditions such as tumors (benign and malignant) of the small
25 intestine and colon,
- 3) ulcero-inflammatory diseases of small intestine and colon such as Crohn's disease and ulcerative colitis, and
- 4) congenital anomalies of small intestine and colon.

The high amino acid sequence identity of VDRR γ with the VDR both in the DNA-
30 binding domain (DBD) and ligand-binding domain (LBD) indicate that these two receptors

may also have overlapping yet distinct functional characteristics. In analogy, retinoic acid receptors (RARs) and retinoid X receptors (RXRs) have similar amino acid sequence identities in the DBD and LBD region as the VDR and VDRR γ . RARs and RXRs have been shown to have distinct functional similarities such that both receptors bind 9-cis retinoic acid and have overlapping DNA-binding specificities and accordingly regulate overlapping gene networks. Based on these findings, VDRR γ may be regulated by small chemical molecules similar in structure to known ligands for nuclear receptors but not necessarily identical to ligands for the 1 α , 25-dihydroxy vitamin D3 receptor. Furthermore, VDRR γ may regulate vitamin D3 responsive gene networks by binding to a Vitamin D responsive element (VDRE)-like DNA sequence. In the present application, the 1 α , 25-dihydroxy vitamin D3 receptor is abbreviated as the Vitamin D receptor (VDR).

In the present invention, the substance affecting VDRR signal transduction can be any small chemical molecule of natural or synthetic origin, e.g. a carbohydrate such as an aromatic compound. The small molecule may have a molecular weight in the range of from about 100 up to about 500 Da. Suitably, the small chemical molecule has a molecular weight in the range of from 200 up to 400 Da. Preferably, the small chemical molecule has a molecular weight of about 300 Da.

The human VDRR γ polypeptides, including VDRR γ -1 and VDRR γ -2, have been shown to be activated e.g. by pregnenolones and estradiol (weakly), but not by certain other steroid hormones such as cortisol, aldosterone, progesterone and estrogen, and most likely not by progestines and glucocorticoids. Thus, human VDRR γ is not activated by pregnenolone 16 α -carbonitrile (PCN), a glucocorticoid antagonist. For this reason, human VDRR γ can also be designated human pregnenolone activated (nuclear) receptors (hPAR). Information about pregnenolone can be found e.g. in the Merck Index, 11th ed., Merck & Co., Inc. Rahway, N.J., USA, p. 7735, 1989.

Activators for human VDRR γ polypeptides, including VDRR γ -1 and VDRR γ -2, (hPAR-1 and hPAR-2, respectively), include but are not limited to pregnenolones, such as pregnane-ones, pregnane-diones, pregnane-triones, and pregnane-diols, and androstanes, such as androstane-ols, and androstane-diols. Suitably, the pregnenolones are non-planar, particularly 5 β -pregnanes.

Specific examples of activators and possibly ligands for human VDRR γ polypeptides, including VDRR γ -1 and VDRR γ -2, are the following compounds, which are marketed by Sigma-Aldrich of Sweden:

- i) 5 β -pregnane-3,20-dione
- 5 ii) 3 α -hydroxy-5 β -pregnane-11,20-dione methanesulphonate
- iii) 5 β -pregnane-3 α ,20 β -diol
- iv) pregnenolone
- v) Pregn-4-eno[16,17- δ][2]isoxazolline-3,20-dione, 6 α -methyl-3'-phenyl-, ethyl ether solvate
- 10 vi) Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-[6-methoxy-2-(4-morpholinyl)-4-pyrimidinyl]-1-piperazinyl]-16-methyl-, (16 α)-
- vii) Estran-3-ol, 17-[[[3-(trifluoromethyl)phenyl]methyl]amino]-, (E)-2-butenedioate (1:1) (salt)
- viii) 9 α -Fluoro-5 α -androstane-11 β ,17 β -diol
- 15 ix) Spiro[5 α -androstane-3,2'-benzothiazolin]-11-one, 17 β -hydroxy-17-methyl-
- x) Spiro[pregnane-3,2'-thiazolidine]-4'-carboxylic acid, 11 α -hydroxy-20-oxo-, sodium salt
- xi) 17 β -Dimethylamino-17-ethynyl-5 α -androstane-11 β -ol
- xii) 6 β -Hydroxy-3,5-cyclo-5 α -pregnan-20-one, nitrite
- 20 xiii) 3 α -Hydroxy-5 β -pregnane-11,20-dione, acetate, 20-O-(methylsulfonyl)-oxime
- xiv) 17 α -Methyl-5 α -androstane-11 β ,17-diol
- xv) 5 β -Pregnane-3,11,20-trione, trioxime
- xvi) 3 α -Hydroxy-5 β -pregnane-11,20-dione, 20-hydazone with hydrazide of 1-(carboxymethyl) pyridinium chloride.
- 25 A possible use of a VDRR γ antagonist, could be a synergistic co-administration of the VDRR γ antagonist together with other drugs such as, but not limited to, HIV protease inhibitors and cyclosporin to inhibit the expression of CYP3A4 and thus increase the bioavailability of drugs with poor pharmacokinetics due to CYP3A4 metabolism.
- Genes coding for polypeptides, such as human vitamin D receptor related gamma
- 30 (hVDRR γ), may be cloned by incorporating a DNA fragment coding for the polypeptide into a recombinant DNA vehicle, e.g. a vector, and transforming suitable prokaryotic or

eukaryotic host cells. Such recombinant DNA techniques are well known and e.g. described in Methods in Enzymology, Academic Press, San Diego, CA, USA (1994), vols. 65 and 68 (1979), and vols. 100 and 101 (1983).

The host cells for use in the present invention can be prokaryotic or eukaryotic, preferably eukaryotic cells. Suitable eukaryotic host cells include but are not limited to cells from yeast, e.g. Saccharomyces, insect cells and mammalian cells such as Chinese Hamster Ovary (CHO), Baby Hamster Kidney (BHK), COS and the like. Suitable prokaryotic host cells include but are not limited to cells from Enterobacteriaceae, e.g. E. coli, Bacillus and Streptomyces.

10

EXAMPLES

The following Examples are provided for purposes of illustration only and are not to be construed as in any way limiting the scope of the present invention, which is defined by the appended claims.

15

EXAMPLE 1

Identification and isolation of human VDRRg cDNA

Expressed Sequence Tag (EST) databases were screened for nuclear receptor related sequences with a DNA-binding domain (DBD) profile of nuclear receptors. This search profile was created by multiple alignment of a selected set of nuclear receptor sub-domains followed by a statistical calculation to obtain a so called Hidden Markov Model (HMM) of different subfamily members of the nuclear receptor supergene family. The cDNA of one of the nuclear receptor related EST sequences identified (Incyte clone no 2211526) was analyzed in detail by sequencing. After DNA sequencing of the entire Incyte cDNA clone (approximately 2200 basepairs) the clone was found to encode a putative ligand-binding domain (LBD) with 54% and 44% similarity to xONR-1 and to the vitamin D receptor (VDR), respectively. The cDNA of the Incyte clone was not full-length and did not encode a sequence corresponding to a complete DBD.

30

5'-RACE (rapid amplification of cDNA ends) of random primed cDNA from human liver RNA (InVitrogen) followed by cloning and DNA sequencing showed that the 5'-part of the cDNA corresponding to the Incyte clone encoded a DBD characteristic for nuclear receptors and with 71% and 65% sequence similarity to xONR-1 and VDR, respectively.

- 5 Multiple alignments in combination with evolutionary neighbor-joining tree analysis placed the polypeptide encoded by the cDNA (specified in Fig. 1) in the group of VDRs (Figs. 2 and 3) and was named human vitamin D receptor related gamma (VDRRg). The deduced amino acid sequence of VDRRg is given in Fig. 4.

10 EXAMPLE 2

Expression of VDRRg mRNA in human tissues

- Multiple tissue northern blots (Clontech) was used to determine the expression pattern of VDRRg in adult human tissues. As shown in Fig. 5, VDRRg is abundantly expressed in small intestine, mucosal lining of colon and liver but not in several other tissues
- 15 including spleen, thymus, prostate, testis, ovary, peripheral blood leukocytes, heart, brain, placenta, lung, skeletal muscle, kidney and pancreas. To investigate if VDRRg was expressed at lower levels in any of the other tissues examined, the filter was exposed for an extended time (one week as compared to overnight). Even after this prolonged exposure (data not shown), expression could still only be detected in the same tissues and not in any
- 20 of the other tissues examined. The restricted expression pattern of VDRRg suggest that this receptor is likely to have an important regulatory function in liver and intestine.

EXAMPLE 3

Transient transfections of GAL4-DBD/VDRRg-LBD fusion protein using Vitamin D3

- 25 Transient transfections were performed to analyze if vitamin D3 activate the VDRRg polypeptide. To this end, transient co-transfections of CV-1 cells were performed with expression plasmids encoding fusion proteins of the GAL4-DBD fused to the LBD of either the VDR or the VDRR together with a reporter-plasmid containing five GAL4 responsive elements upstream of the luciferase gene. After transfection, cells were treated with vehicle
- 30 (DMSO) alone or with vitamin D3 for 48 hours followed by harvesting of the cells and measurement of the luciferase activity in cell extracts. As shown in Fig. 6, vitamin D3 (1

μM) transactivate the GAL4-DBD/VDR-LBD but not the corresponding GAL4-DBD/-VDRRγ-LBD polypeptide under these conditions. This indicates that the two receptors may have distinct ligand-binding specificities.

5 EXAMPLE 4

Identification and isolation of human VDRRγ cDNAs encoding multiple N-terminal isoforms

5'-RACE (see Example 1) of cDNA from human liver RNA followed by cloning and DNA sequencing identified an additional human VDRRγ cDNA with alternatively spliced
10 5'-end (see Fig. 7). The VDRRγ cDNAs are thus able to encode at least one alternative N-terminal variant (Fig. 8) in addition to the VDRRγ polypeptide shown in Fig. 4. The polypeptides disclosed in Fig. 4 and Fig. 8 which correspond to the differentially spliced VDRRγ cDNAs are designated as VDRRγ-1 and VDRRγ-2, respectively.

15

EXAMPLE 5

VDRRγ heterodimerise with RXR and bind to direct repeats (DRs) spaced by three or four nucleotides

Expression plasmids containing VDRRγ or RXRβ cDNAs were transcribed using T7
20 polymerase and translated *in vitro* in TNT reticulocyte lysates (Promega, Madison, WI, USA). To investigate the DNA-binding specificity of VDRRγ a native gel mobility assay was employed essentially as described (Berkenstam et al., Cell, 69, 401-412, 1992) in which *in vitro* translated VDRRγ was incubated in the presence or absence of *in vitro* translated RXRβ with different 32P-labelled direct repeats (DR-1 to DR-5) as indicated in Fig. 9. The
25 direct repeats were derived from the DR-5 element in the RAR-β2 promoter (de Thé et al., Nature, 343, 177-180, 1990) and modified to be separated by one to five nucleotides (Pettersson et al., Mechanisms of Dev., 54, 1-13, 1995). Protein-DNA complexes were separated on native 5% polyacryl-amide/0.25xTBE gels followed by autoradiography. As shown in Fig. 9, of the five DRs tested efficient VDRRγ binding could only be detected
30 with DRs separated by three or four nucleotides and only in the presence of RXR. However, weaker RXR-dependent binding could also be observed to DR-2 and DR-1 elements. These

results demonstrate that VDRR γ require RXR heterodimerisation for efficient DNA-binding to a specific subset of DRs. These results, however, do not exclude the possibility that VDRR γ may bind as a monomer, dimer or heterodimer to distinct but related DNA-sequences. Importantly, our results demonstrate that VDRR γ and other nuclear receptors including the VDR (e.g. Markose, E. R. et al., Proc. Natl. Acad. Sci. USA, 87, 1701-1705, 1990), THR α s (e.g. Gronemeyer, H. and Moras, D., Nature, 375, 190-191, 1995), LXR α s (e.g. Willy, P. J. et al., Genes. Dev., 9, 1033-1045, 1995), have distinct but overlapping DNA-sequence and thus may regulate overlapping gene networks.

Interestingly, the most closely related nuclear receptor called ONR-1 (in Smith et al., 1994, Nucleic Acids Res., 22, pp66-71) or XOR-6 (in WO 96/22390) have been reported to “bind well to a retinoic acid response element, bRARE” (p. 11, line 30 in WO 96/22390). However, although the novel nuclear receptor VDRR γ reported herein has 71% amino acid similarity in the DBD as compared to XOR-6 (fig 12), VDRR γ does not appear to bind to the same bRARE sequence (DR-5 in Fig. 9).

15

EXAMPLE 6

Pregnenolone derivatives as activators of VDRR γ

For identifying activators or ligands for VDRR γ , a library of substances structurally biased towards different classes of activators and ligands for nuclear receptors were tested.

The activation of VDRR γ was analyzed in a reporter gene assay in transiently Caco-2 (TC7) cells (Carriere et al, 1994). In this initial screen, the synthetic substances with ability to activate VDRR γ were found to be structurally similar to pregnenolones (data not shown). Based on these results, naturally occurring pregnenolone derivatives were examined for activation of VDRR γ . The results are shown in Fig. 10. As is evident from Fig. 10, VDRR γ was activated about 5 to 12 fold by pregnenolone, 5 β -pregnane-3,20-dione, 5 β -pregnane-3 α ,20 β -diol and 3 α -hydroxy-5 β -pregnane-11,20-dione methanesulphonate. In contrast to the efficient activation observed by the 5 β -pregnane-3,20-dione, the corresponding planar steroid derivative 5 α -pregnane-3,20-dione did not activate the receptor. Other 5 β -pregnanes also activated VDRR γ efficiently as opposed to all planar pregnenolone derivatives tested, as is also evident from Fig. 10.

30

EXAMPLE 7

Pregnenolone 16 α -carbonitrile (PCN), dexamethasone and an antiprogesterin (RU486) as activators of VDRR γ

Further experiments were performed to find out if pregnenolone 16 α -carbonitrile (PCN), a glucocorticoid antagonist or dexamethasone are activators of VDRR γ . To this effect, Caco-2 cells were transfected as before with VDRR γ and the activation was analyzed after treatment of the cells with 10 μ M PCN or dexamethasone. The results are shown in Fig. 11. As is evident from Fig. 11, VDRR γ was not activated by these substances, indicating that VDRR γ is not the human PCN receptor. This suggestion is corroborated by the observation that also the antiprogesterin RU486 only caused a slight increase (two fold) in VDRR γ mediated reporter gene activity as is evident from Fig. 11.

Activators of XOR-6 (Fig. 3 in WO 96/22390) such as butyl 4-NH₂ Benzoate did not activate VDRR γ (data not shown) in similar reporter assays as used in WO 96/22390.

SEQUENCE LISTING

<110> Pharmacia & Upjohn AB

<120> Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof.

<130> 1788sequence listing

<140>

<141>

<150> 9703745-1

<151> 1997-10-14

<150> 9801148-9

<151> 1998-03-31

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 2910

<212> DNA

<213> Homo sapiens

<400> 1

cctctgaagg ttctagaatc gatagtgaat tcgtgggacg ggaagaggaa gcactgcctt 60
tacttcagtg ggaatctcgg cctcagcctg caagccaagt gttcacagtg aaaaagcaa 120
gagaataagc taatactcct gtctgaaca aggcagcggc tccttggtaa agctactcct 180
tgatcgatcc ttgcaccgg attgtcaaa gtggaccca ggggagaagt cggagcaaag 240
aacttaccac caagcagtc aagaggccca gaagcaaacc tggaggtgag acccaaagaa 300
agctggaacc atgctgactt tgtactgtg gaggacacag agtctgttcc tggaaagccc 360
agtgtcaacg cagatgagga agtcggaggt ccccaaattc gccgtgtatg tggggacaag 420
gccactggct atcaactcaa tgtcatgaca tgtgaaggat gcaagggtt ttcaggagg 480
gccatgaac gcaacgccc gctgagggtc ccttccgga agggcgcctg cgagatcacc 540
cggaagacc ggcgacagt ccaggcctgc cgcctgcga agtcctgga gagcggcatg 600
aagaaggaga tgatcatgtc cgacaggcc gtggaggaga ggcgggcctt gatcaagcgg 660
aagaaaagt aacggacagg gactcagcca ctgggagtgc aggggctgac agaggagcag 720
cggatgatga tcagggagct gatggacgt cagatgaaa ccttgacac taccttctcc 780
cattcaaga attccggct gccaggggtg ctagcagtg gctgcgagtt gccagagtct 840
ctgcaggccc catcgaggga agaagctgcc aagtggagcc aggtccgga agatctgtgc 900
tcttgaagg tctctctgca gtcgggggg gaggatggca gtgtctggaa ctacaaccc 960
ccagccgaca gtggcgggaa agagatctc tcctgtctgc cccatggc tgacatgtca 1020
acctacatgt tcaaaggcat catcagctt gccaaagtca tctctactt cagggacttg 1080

cccatcgagg accagatctc cctgctgaag ggggccgctt tcgagctgtg tcaactgaga 1140
ttcaacacag tgttcaacgc ggagactgga acctgggagt gtggccggct gtctactgc 1200
ttggaagaca ctgcaggtgg ctccagcaa ctctactgg agcccatgct gaaattccac 1260
tacatgctga agaagctgca gctgcatgag gaggagtag tgctgatgca ggccatctcc 1320
ctcttctccc cagaccgccc aggtgtgctg cagcaccgcg tggtaggacca gctgcaggag 1380
caattcgcca ttacttgaa gtctacatt gaatgcaatc ggccccagcc tgctcatagg 1440
ttctgttcc gtgaagatca tggctatgct caccgagctc cgcagcatca atgctcagca 1500
caccagcgg ctgctgcgca tccaggacat acacccctt gctacgcccc tcatgcagga 1560
gttgttcggc atcacagga gctgagcggc tgcccttggg tgacacctcc gagaggcagc 1620
cagaccaga gccctctgag ccgccactcc cgggccaaga cagatggaca ctgccaagag 1680
ccgacaatgc cctgctggcc tgtctcccta gggaattcct gctatgacag ctggctagca 1740
ttctcagga aggacatggg tgccccccac cccagttca gtctgtaggg agtgaagcca 1800
cagactctta cgtggagagt gcactgacct gtaggtcagg accatcagag aggcaaggtt 1860
gcccttctct tttaaaaggc cctgtggtct ggggagaaat ccctcagatc ccactaaagt 1920
gtcaaggtgt ggaagggacc aagcgaccaa ggataggcca tctggggtct atgccacat 1980
accacgitt gtgcgttcc tgagtcttt cattgctacc tctaatagtc ctgtctcca 2040
cttccactc gtccccctcc tcttccgagc tgctttgtgg gctcaaggcc tgtactc 2100
ggcaggtgca tgagtatctg tgggagtct ctgagagat gagaagccag gaggcctgca 2160
ccaatgtca gaagcttggc atgacctcat tccggccaca tcattctgtg tctctgcatc 2220
cattgaaca cattattaag cactgataat aggtagcctg ctgtggggta tacagcattg 2280
actcagatat agatcctgag ctacagagt ttatagttaa aaaaacaaac agaaacacaa 2340
acaatttga tcaaaaggag aaaatgataa gtgacaaaag cagcacaagg aattccctg 2400
tgtggatgct gagctgtgat ggcaggcact gggtagccaa gtgaagggtc ccgaggacat 2460
gagtctgtag gagcaagggc aaaaactgca gctgtgagt cgtgtgtgtg atttggtgta 2520
ggtaggtctg ttgccactt gatggggcct gggtttgtc ctggggctgg aatgctgggt 2580
atgctctgtg acaaggctac gctgacaatc agttaaacac accggagaag aaccatttac 2640
atgcacctta tatttctgtg tacacatcta ttctcaaagc taaagggtat gaaagtcct 2700
gccttgttta tagccacttg tgagtaaaaa ttttttgca tttcacaaa ttatactta 2760
tataaggcat tccacaccta agaactagt ttgggaaatg tagccctggg ttaatgtca 2820
aatcaaggca aaaggaafta aataatgtac tttggctaa aaaaaaaaaa aaaaaaaaaa 2880
aaaaaaaaa aaaaaaaaaa aaaaaagcnt 2910

<210> 2

<211> 437

<212> PRT

<213> Homo sapiens

<400> 2

Met Glu Val Arg Pro Lys Glu Ser Trp Asn His Ala Asp Phe Val His

1 5 10 15

Cys Glu Asp Thr Glu Ser Val Pro Gly Lys Pro Ser Val Asn Ala Asp

20 25 30

Glu Glu Val Gly Gly Pro Gln Ile Cys Arg Val Cys Gly Asp Lys Ala

35 40 45

Thr Gly Tyr His Phe Asn Val Met Thr Cys Glu Gly Cys Lys Gly Phe

50 55 60

Phe Arg Arg Ala Met Lys Arg Asn Ala Arg Leu Arg Cys Pro Phe Arg

65 70 75 80

Lys Gly Ala Cys Glu Ile Thr Arg Lys Thr Arg Arg Gln Cys Gln Ala

85 90 95

Cys Arg Leu Arg Lys Cys Leu Glu Ser Gly Met Lys Lys Glu Met Ile

100 105 110

Met Ser Asp Glu Ala Val Glu Glu Arg Arg Ala Leu Ile Lys Arg Lys

115 120 125

Lys Ser Glu Arg Thr Gly Thr Gln Pro Leu Gly Val Gln Gly Leu Thr

130 135 140

Glu Glu Gln Arg Met Met Ile Arg Glu Leu Met Asp Ala Gln Met Lys

145 150 155 160

Thr Phe Asp Thr Thr Phe Ser His Phe Lys Asn Phe Arg Leu Pro Gly

165 170 175

Val Leu Ser Ser Gly Cys Glu Leu Pro Glu Ser Leu Gln Ala Pro Ser

180 185 190

Arg Glu Glu Ala Ala Lys Trp Ser Gln Val Arg Lys Asp Leu Cys Ser

SUBSTITUTE SHEET (RULE 26)

195 200 205
Leu Lys Val Ser Leu Gln Leu Arg Gly Glu Asp Gly Ser Val Trp Asn
210 215 220
Tyr Lys Pro Pro Ala Asp Ser Gly Gly Lys Glu Ile Phe Ser Leu Leu
225 230 235 240
Pro His Met Ala Asp Met Ser Thr Tyr Met Phe Lys Gly Ile Ile Ser
245 250 255
Phe Ala Lys Val Ile Ser Tyr Phe Arg Asp Leu Pro Ile Glu Asp Gln
260 265 270
Ile Ser Leu Leu Lys Gly Ala Ala Phe Glu Leu Cys Gln Leu Arg Phe
275 280 285
Asn Thr Val Phe Asn Ala Glu Thr Gly Thr Trp Glu Cys Gly Arg Leu
290 295 300
Ser Tyr Cys Leu Glu Asp Thr Ala Gly Gly Phe Gln Gln Leu Leu Leu
305 310 315 320
Glu Pro Met Leu Lys Phe His Tyr Met Leu Lys Lys Leu Gln Leu His
325 330 335
Glu Glu Glu Tyr Val Leu Met Gln Ala Ile Ser Leu Phe Ser Pro Asp
340 345 350
Arg Pro Gly Val Leu Gln His Arg Val Val Asp Gln Leu Gln Glu Gln
355 360 365
Phe Ala Ile Thr Leu Lys Ser Tyr Ile Glu Cys Asn Arg Pro Gln Pro
370 375 380
Ala His Arg Phe Leu Phe Leu Lys Ile Met Ala Met Leu Thr Glu Leu
385 390 395 400
Arg Ser Ile Asn Ala Gln His Thr Gln Arg Leu Leu Arg Ile Gln Asp
405 410 415
Ile His Pro Phe Ala Thr Pro Leu Met Gln Glu Leu Phe Gly Ile Thr
420 425 430
Gly Ser Phe Ile Gly
435

SUBSTITUTE SHEET (RULE 26)

<210> 3

<211> 2802

<212> DNA

<213> Homo sapiens

<400> 3

tgaattcgtg ggcctgctgg gttagtctg gcagcccccc tgaggccaag gacagcagca 60
tgacagtcac caggactcac cactcaagg aggggtccct cagagcacct gccatacccc 120
tgcacagtgc tgcggctgag ttggcttcaa accatccaag aggcccagaa gcaaacctgg 180
aggtagagacc caaagaaaagc tggaaccatg ctgactttgt acactgtgag gacacagagt 240
ctgttctctg aaagcccagt gtcaacgcag atgaggaagt cggaggtccc caaatctgcc 300
gtgtatgtgg ggacaaggcc actggctatc acttcaatgt catgacatgt gaaggatgca 360
agggtctttt caggagggcc atgaaacgca acgcccggct gaggtgcccc ttccggaagg 420
gcgcctgcga gatcaccgag aagaccgggc gacagtgccg ggcctgccgc ctgcgcaagt 480
gcctggagag cggcataaag aaggagatga tcatgtccga cgaggccgtg gaggagaggc 540
gggccttgat caagcggaag aaaagtgaac ggacaggggac tcagccactg ggagtgcagg 600
ggctgacaga ggagcagcgg atgatgatca gggagctgat ggacgctcag atgaaaacct 660
ttgacactac cttctcccat ttcaagaatt tccggctgcc aggggtgctt agcagtggct 720
gcgagttgcc agagtctctg caggcccat cgagggaaga agctgccaag tggagccagg 780
tccgaaaga tctgtgctt ttgaaggctt ctctgcagct gcggggggag gatggcagt 840
tctggaacta caaaccccca gccgacagt gcgggaaaga gatcttctcc ctgctgcccc 900
acatggctga catgtcaacc tacatgttca aaggcatcat cagctttgcc aaagtcact 960
cctacttcag ggacttgccc atcgaggacc agatctccct gctgaagggg gccgctttcg 1020
agctgtgtca actgagattc aacacagtgt tcaacgcgga gacttgaacc tgggagtgtg 1080
gccggctgtc ctactgcttg gaagacactg cagggtgctt ccagcaactt ctactggagc 1140
ccatgtgaa attccactac atgtgaaga agctgcagct gcatgaggag gagtatgtgc 1200
tgatgcaggc catctccctc ttctcccag accgcccagg tgtgctgcag caccgcgtgg 1260
tggaccagct gcaggagcaa ttcgccatta ctctgaagtc ctacattgaa tgcaatcggc 1320
cccagcctgc tcataggttc ttgttctga agatcatggc tatgtcacc gagctccga 1380
gcatcaatgc tcagcacacc cagcggctgc tgcgcatcca ggacatacac cctttgcta 1440

cgccctcat gcaggagtgc ttggcatca caggtagctg agcggctgcc cttgggtgac 1500
 acctccgaga ggcagccaga cccagagccc tctgagccgc cactcccggg ccaagacaga 1560
 tggacactgc caagagccga caatgccctg ctggcctgtc tccctaggga attcctgcta 1620
 tgacagctgg ctagcattcc tcaggaagga catgggtgcc cccaccccc agttcagtct 1680
 gtagggagtg aagccacaga ctctacgtg gagagtgcac tgacctgtag gtcaggacca 1740
 tcagagaggg aaggtgccc tttctttta aaaggccctg tggctgggg agaaatccct 1800
 cagatccac taaagtgtca aggtgtggaa gggaccaagc gaccaaggat aggccatctg 1860
 gggctctatgc ccacataccc acgtttgttc gcttctgag tcttttcatt gctacctcta 1920
 atagtctgt ctccacttc cactcgttc cctcctctt ccgagctgct ttgtgggctc 1980
 aaggcctgta ctcatcggga ggtgcatgag tatctgtggg agtcctctag agagatgaga 2040
 agccaggagg cctgcaccaa atgcagaag ctggcatga cctcattccg gccacatcat 2100
 tctgtgtctc tgcattcatt tgaacacatt attaagcact gataataggt agcctgctgt 2160
 ggggtatata gcattgactc agatatagat cctgagctca cagagtttat agttaaaaa 2220
 acaaacagaa acacaaacaa ttggatcaa aaggagaaaa tgataagtga caaaagcagc 2280
 acaaggaatt tcctgtgtg gatgctgagc tgtgatggca ggcactgggt acccaagtga 2340
 aggttccga ggacatgagt ctgtaggagc aagggcacaa actgcagctg tgagtgcgtg 2400
 tgtgtgattt ggtgtaggta ggtctgtttg ccacttgatg gggcctgggt ttgttctgg 2460
 ggctggaatg ctgggtatgc tctgtgacaa ggctacgctg acaatcagtt aaacacaccg 2520
 gagaagaacc atttatgc accatatatt tctgtgtaca catctattct caaagctaaa 2580
 gggtatgaaa gtgcctgcct tgtttatagc cacttgtag taaaaatit ttgcatttt 2640
 cacaaattat actttatata aggcattcca cacctaagaa ctagttttgg gaaatgtagc 2700
 cctgggttta atgtcaaatc aaggcaaaag gaattaaata atgtactttt ggctaaaaaa 2760
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 2802

<210> 4

<211> 473

<212> PRT

<213> Homo sapiens

<400> 4

Met	Thr	Val	Thr	Arg	Thr	His	His	Phe	Lys	Glu	Gly	Ser	Leu	Arg	Ala
1			5			10			15						

SUBSTITUTE SHEET (RULE 26)

Pro Ala Ile Pro Leu His Ser Ala Ala Ala Glu Leu Ala Ser Asn His
20 25 30

Pro Arg Gly Pro Glu Ala Asn Leu Glu Val Arg Pro Lys Glu Ser Trp
35 40 45

Asn His Ala Asp Phe Val His Cys Glu Asp Thr Glu Ser Val Pro Gly
50 55 60

Lys Pro Ser Val Asn Ala Asp Glu Glu Val Gly Gly Pro Gln Ile Cys
65 70 75 80

Arg Val Cys Gly Asp Lys Ala Thr Gly Tyr His Phe Asn Val Met Thr
85 90 95

Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ala Met Lys Arg Asn Ala
100 105 110

Arg Leu Arg Cys Pro Phe Arg Lys Gly Ala Cys Glu Ile Thr Arg Lys
115 120 125

Thr Arg Arg Gln Cys Gln Ala Cys Arg Leu Arg Lys Cys Leu Glu Ser
130 135 140

Gly Met Lys Lys Glu Met Ile Met Ser Asp Glu Ala Val Glu Glu Arg
145 150 155 160

Arg Ala Leu Ile Lys Arg Lys Lys Ser Glu Arg Thr Gly Thr Gln Pro
165 170 175

Leu Gly Val Gln Gly Leu Thr Glu Glu Gln Arg Met Met Ile Arg Glu
180 185 190

Leu Met Asp Ala Gln Met Lys Thr Phe Asp Thr Thr Phe Ser His Phe
195 200 205

Lys Asn Phe Arg Leu Pro Gly Val Leu Ser Ser Gly Cys Glu Leu Pro
210 215 220

Glu Ser Leu Gln Ala Pro Ser Arg Glu Glu Ala Ala Lys Trp Ser Gln
225 230 235 240

Val Arg Lys Asp Leu Cys Ser Leu Lys Val Ser Leu Gln Leu Arg Gly
245 250 255

Glu Asp Gly Ser Val Trp Asn Tyr Lys Pro Pro Ala Asp Ser Gly Gly
260 265 270

SUBSTITUTE SHEET (RULE 26)

Lys Glu Ile Phe Ser Leu Leu Pro His Met Ala Asp Met Ser Thr Tyr
275 280 285

Met Phe Lys Gly Ile Ile Ser Phe Ala Lys Val Ile Ser Tyr Phe Arg
290 295 300

Asp Leu Pro Ile Glu Asp Gln Ile Ser Leu Leu Lys Gly Ala Ala Phe
305 310 315 320

Glu Leu Cys Gln Leu Arg Phe Asn Thr Val Phe Asn Ala Glu Thr Gly
325 330 335

Thr Trp Glu Cys Gly Arg Leu Ser Tyr Cys Leu Glu Asp Thr Ala Gly
340 345 350

Gly Phe Gln Gln Leu Leu Leu Glu Pro Met Leu Lys Phe His Tyr Met
355 360 365

Leu Lys Lys Leu Gln Leu His Glu Glu Glu Tyr Val Leu Met Gln Ala
370 375 380

Ile Ser Leu Phe Ser Pro Asp Arg Pro Gly Val Leu Gln His Arg Val
385 390 395 400

Val Asp Gln Leu Gln Glu Gln Phe Ala Ile Thr Leu Lys Ser Tyr Ile
405 410 415

Glu Cys Asn Arg Pro Gln Pro Ala His Arg Phe Leu Phe Leu Lys Ile
420 425 430

Met Ala Met Leu Thr Glu Leu Arg Ser Ile Asn Ala Gln His Thr Gln
435 440 445

Arg Leu Leu Arg Ile Gln Asp Ile His Pro Phe Ala Thr Pro Leu Met
450 455 460

Gln Glu Leu Phe Gly Ile Thr Gly Ser
465 470

CLAIMS

1. A mammalian, preferably human, isolated or recombinant nucleic acid comprising a contiguous nucleic acid sequence encoding a vitamin D receptor related (VDRR) polypeptide.
2. An isolated or recombinant DNA/nucleic acid according to Fig. 1 or Fig. 7 or alleles thereof encoding a new VDRR polypeptide.
3. The nucleic acid according to claim 1 or claim 2 encoding the VDRR polypeptide containing a DNA-binding domain (DBD) comprising about 77 amino acids with 9 cysteine residues,, wherein said DBD is characterized by the following amino acid sequence similarity:
 - (i) at least 60% amino acid sequence similarity with the DBD of hVDR; and
 - (ii) at least 65% amino acid sequence similarity with the DBD of xONR1.
4. The nucleic acid according to claim 3, wherein said DBD is characterized by the following amino acid sequence similarity:
 - (i) about 65% amino acid sequence similarity with the DBD of hVDR; and
 - (ii) about 71% amino acid sequence similarity with the DBD of xONR1.
5. The nucleic acid according to any previous claim, encoding the VDRR polypeptide, wherein the ligand-binding domain (LBD) of said polypeptide is characterized by the following amino acid sequence similarity, relative to the LBDs of hVDR and xONR1, respectively:
 - (i) at least about 30% amino acid sequence similarity with the LBD of hVDR; and
 - (ii) at least about 40% amino acid sequence similarity with the LBD of xONR1.

6. The nucleic acid according to claim 5, wherein said LBD is characterized by the following amino acid sequence similarity:
- (i) at least 35% amino acid sequence similarity with the LBD of hVDR; and
 - (ii) at least 45% amino acid sequence similarity with the LBD of xONR1.
7. The nucleic acid according to claim 6, wherein said LBD is characterized by the following amino acid sequence similarity:
- (i) about 42% amino acid sequence similarity with the LBD of hVDR; and
 - (ii) about 54% amino acid sequence similarity with the LBD of xONR1.
8. The nucleic acid according to any previous claim, wherein said nucleic acid sequence is that given in Fig. 1 or Fig. 7 or alleles thereof.
9. The nucleic acid according to claim 8, wherein said nucleic acid sequence is the same or substantially the same as given in Fig. 1 or Fig. 7.
10. A nucleic acid probe for the detection of a nucleic acid sequence encoding a VDRR polypeptide in a sample.
11. The nucleic acid probe according to claim 10, wherein said probe comprises at least 14 contiguous nucleotides of the nucleic acid sequence given in Fig. 1 or Fig. 7.
12. A method for identifying clones encoding a VDRR polypeptide said method comprising screening a genomic or cDNA library with a nucleic acid probe according to claims 10 or 11 under low stringency hybridization conditions, and identifying those clones which display a substantial degree of hybridization to said probe.
13. An expression vector comprising a nucleic acid according to any of claims 1 -9.

14. A cell containing a nucleic acid according to any of claims 1 -9.
15. A cell containing an expression vector according to claim 14.
16. A process for recombinant production of a VDRR polypeptide, said process comprising expressing the nucleic acid of claims 1 to 9 in a suitable host cell.
17. The process according to claim 16, wherein the host cell is eukaryotic.
18. An isolated or recombinant mammalian, preferably human, VDRR polypeptide.
19. The isolated or recombinant VDRR polypeptide according to claim 18 comprising the amino acid sequence substantially the same or the same as given in Fig. 4 or Fig. 8.
20. A method to produce specific monoclonal and polyclonal antibodies to the polypeptide according to any of claims 18 and 19 comprising the injection of the protein to a mammalian.
21. A pharmaceutical formulation comprising an isolated or recombinant VDRR polypeptide according to claims 18 or 19, and one or more therapeutically acceptable excipients.
22. A method for identifying a ligand to a VDRR, by a cell-based reporter assay, transgenic-animal reporter assay or *in vitro*-binding assay.
23. A method for identifying a substance for treatment of a condition affected by a VDRR polypeptide, comprising screening for an agonist or an antagonist of VDRR polypeptide signal transduction to be used for treating metabolic, proliferative or inflammatory conditions.

24. A mammalian, preferably human, VDRR polypeptide according to any of claims 18 and 19 for use as a medicament.
25. Use of a substance affecting VDRR signal transduction, such as an agonist or an antagonist of VDRR polypeptide signal transduction, for the manufacture of a medicament for treating metabolic, proliferative or inflammatory conditions.
26. Use according to claim 25 of a substance affecting VDRR signal transduction for the manufacture of a medicament for treating obesity, diabetes, anorexia, lipoprotein defects, hyperlipidemia, hypercholesteremia or hyperlipoproteinemia.
27. Use of a substance affecting VDRR signal transduction for the manufacture of a medicament for treating osteoporosis, rheumatoid arthritis, benign and malign tumors, hyperproliferative skin disorders or hyperparathyroidism.
28. Use according to any of claims 25-27, wherein the substance affecting VDRR signal transduction is a chemical molecule of natural or synthetic origin with a molecular weight in the range of from about 100 up to about 500 Da, preferably with a molecular weight of about 300 Da.
29. A method for treating metabolic, proliferative or inflammatory conditions comprising introducing into a mammal a nucleic acid vector according to claim 13 encoding for expression of a VDRR polypeptide and wherein said nucleic acid vector is capable of transforming a cell *in vivo* and expressing said polypeptide in said transformed cell.
30. A method for treatment of a metabolic, proliferative or inflammatory condition by administration of a therapeutically effective amount of a substance affecting VDRR signal transduction.

31. The method according to claim 30, wherein the substance affecting VDRR signal transduction is a chemical molecule of natural or synthetic origin with a molecular weight in the range of from about 100 up to about 500 Da, preferably with a molecular weight of about 300 Da.

1/15

1 CCTCTGAAGG TTCTAGAA TC GATAGTGAAT TCCTGGGACG GGAAGAGGAA
51 GCACTGCCCTT TACTTCAGTG GGAATCTCGG CTTACGCTTG CAAGCCAAGT
101 GTTCACAGTG AAAAAAGCAA GAGAATAAGC TAATACTCCT GTCTTGAACA
151 AGGCAGCGGC TCCTTGGTAA AGCTACTCCT TGATCGATCC TTTGCACCGG
201 ATTGTTCAAA GTGGACCCCA GGGGAGAAGT CGGAGCAAAG AACTTACCAC
251 CAAGCAGTCC AAGAGGCCCA GAAGCAAACC TGGAGGTGAG ACCCAAAGAA
301 AGCTGGAACC ATGCTGACTT TGTACACTGT GAGGACACAG AGTCTGTTCC
351 TGGAAAGCCC AGTGTCAACC CAGATGAGGA AGTCGGAGGT CCCCAAATCT
401 GCCGTGTATG TGGGGACAAG GCCACTGGCT ATCACTTCAA TGTCAATGACA
451 TGTGAAGGAT GCAAGGGCTT TTTCAGGAGG GCCATGAAAC GCAACGCCCG
501 GCTGAGGTGC CCCTTCCGA AGGGCGCCTG CGAGATCACC CGGAAGACCC
551 GCGACAGTG CCAGGCCTGC CGCCTGCGCA AGTGCCCTGGA GAGCGGCATG
601 AAGAAGGAGA TGATCATGTC CGACGAGGCC GTGGAGGAGA GCGGGCCTT
651 GATCAAGCGG AAGAAAAGTG AACGGACAGG GACTCAGCCA CTGGGAGTGC
701 AGGGGCTGAC AGAGGAGCAG CGGATGATGA TCAGGGAGCT GATGGACGCT
751 CAGATGAAAA CCTTTGACAC TACCTTCTCC CATTTCAAGA ATTTCCGGCT
801 GCCAGGGGTG CTTAGCAGTG GCTGCGAGTT GCCAGAGTCT CTGCAGGCC
851 CATCGAGGGA AGAAGCTGCC AAGTGGAGCC AGGTCCGGAA AGATCTGTGC
901 TCTTTGAAGG TCTCTCTGCA GCTGCGGGGG GAGGATGGCA GTGTCTGGAA
951 CTACAAACCC CCAGCCGACA GTGGCGGGAA AGAGATCTTC TCCCTGCTGC
1001 CCCACATGGC TGACATGTCA ACCTACATGT TCAAAGGCAT CATCAGCTTT
1051 GCCAAAGTCA TCTCCTACTT CAGGGACTTG CCCATCGAGG ACCAGATCTC
1101 CCTGCTGAAG GGGGCCGCTT TCGAGCTGTG TCAACTGAGA TTCAACACAG
1151 TGTTCAACGC GGAGACTGGA ACCTGGGAGT GTGGCCGGCT GTCCTACTGC
1201 TTGGAAGACA CTGCAGGTGG CTTCCAGCAA CTTCTACTGG AGCCCATGCT
1251 GAAATTCCAC TACATGCTGA AGAAGCTGCA GCTGCATGAG GAGGAGTATG
1301 TGCTGATGCA GGCCATCTCC CTCTTCTCCC CAGACCGCCC AGGTGTGCTG
1351 CAGCACCGCG TGGTGGACCA GCTGCAGGAG CAATTCGCCA TTA CTCTGAA
1401 GTCCTACATT GAATGCAATC GGCCCCAGCC TGCTCATAGG TTCTTGTTC

Fig. 1

2/15

1451 TGAAGATCAT GGCTATGCTC ACCGAGCTCC GCAGCATCAA TGCTCAGCAC
1501 ACCCAGCGGC TGCTGCGCAT CCAGGACATA CACCCCTTTG CTACGCCCTT
1551 CATGCAGGAG TTGTTCGGCA TCACAGGTAG CTGAGCGGCT GCCCTTGGGT
1601 GACACCTCCG AGAGGCAGCC AGACCCAGAG CCCTCTGAGC CGCCACTCCC
1651 GGGCCAAGAC AGATGGACAC TGCCAAGAGC CGACAATGCC CTGCTGGCCT
1701 GTCTCCCTAG GGAAATCCTG CTATGACAGC TGGCTAGCAT TCCTCAGGAA
1751 GGACATGGGT GCCCCCACC CCCAGTTCAG TCTGTAGGGA GTGAAGCCAC
1801 AGACTCTTAC GTGGAGAGTG CACTGACCTG TAGGTCAGGA CCATCAGAGA
1851 GGCAAGGTTG CCCTTTCCTT TTAAGAGGCC CTGTGGTCTG GGGAGAAATC
1901 CCTCAGATCC CACTAAAGTG TCAAGGTGTG GAAGGGACCA AGCGACCAAG
1951 GATAGGCCAT CTGGGGTCTA TGCCACATA CCCACGTTT TCGCTTCCT
2001 GAGTCTTTT ATTGCTACCT CTAATAGTCC TGTCTCCAC TTCCCACTCG
2051 TTCCCTCCT CTTCGAGCT GCTTGTGGG CTCAAGGCCT GTACTCATCG
2101 GCAGGTGCAT GAGTATCTGT GGGAGTCTC TAGAGAGATG AGAAGCCAGG
2151 AGGCCTGCAC CAAATGTCAG AAGCTTGGCA TGACCTCATT CCGGCCACAT
2201 CATTCTGTGT CTCTGCATCC ATTTGAACAC ATTATTAAAGC ACTGATAATA
2251 GGTAGCCTGC TGTGGGGTAT ACAGCATTGA CTCAGATATA GATCCTGAGC
2301 TCACAGAGTT TATAGTTAAA AAAACAAACA GAAACACAAA CAATTTGGAT
2351 CAAAAGGAGA AAATGATAAG TGACAAAAGC AGCACAAGGA ATTTCCCTGT
2401 GTGGATGCTG AGCTGTGATG GCAGGCACTG GGTACCCAAG TGAAGGTTCC
2451 CGAGGACATG AGTCTGTAGG AGCAAGGGCA CAACTGCAG CTGTGAGTGC
2501 GTGTGTGTGA TTTGGTGTAG GTAGGTCTGT TTGCCACTTG ATGGGGCCTG
2551 GGTGTGTTCC TGGGGCTGGA ATGCTGGGTA TGCTCTGTGA CAAGGCTACG
2601 CTGACAATCA GTTAAACACA CCGGAGAAGA ACCATTTACA TGCACCTTAT
2651 ATTTCTGTGT ACACATCTAT TCTCAAAGCT AAAGGGTATG AAAGTGCCTG
2701 CCTTGTTTAT AGCCACTTGT GAGTAAAAAT TTTTTTGCAT TTCACAAAT
2751 TATACTTTAT ATAAGGCATT CCACACCTAA GAACTAGTTT TGGGAAATGT
2801 AGCCCTGGGT TTAATGTCAA ATCAAGGCAA AAGGAATTAA ATAATGTACT
2851 TTTGGCTAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA
2901 AAAAA

Fig. 1 (cont.)

3/15

Evolutionary Neighbour-Joining Tree




Fig. 2

SUBSTITUTE SHEET (RULE 26)

4/15

Evolutionary Neighbour-Joining Tree




Fig. 3

SUBSTITUTE SHEET (RULE 26)

5/15

1 MEVRPKESWN HADFVHCEDT ESVP GKPSVN ADEEVGGPQI CRVCGDKATG
51 YHFNVMTC EG CKGFFRRAMK RNARLRCPFR KGACEITRKT RRQCQACRLR
101 KCLESGMKKE MIMSDEAVEE RRALIKRKKS ERTGTQPLGV QGLTEEQRMM
151 IRELMDAQMK TFDTTFSHK NFRLPGVLSS GCELPESLQA PSREEAAKWS
201 QVRKDLCSLK VSLQLRGEDG SVWNYKPPAD SGGKEIFSLL PHMADMSTYM
251 FKGIISFAKV ISYFRDLPIE DQISLLKGAA FELCQLRFNT VFNAETGTWE
301 CGRLSYCLED TAGGFQQLLL EPMLKFHYML KKLQLHEEEY VLMQAISLFS
351 PDRPGVLQHR VVDQLQEQA ITLKSYIECN RPQPAHRFLF LKIMAMLT EL
401 RSINAQHTQR LLRIQDIHPF ATPLMQELFG ITGS

Fig. 4

6/15




Fig. 5

7/15




Fig. 6

8/15

```

TGAATTGCTGGGCTGCTGGGTAGTGCTGGCAGXXXXXX 40
TGAGGCCAAGGACAGCAGCATGACAGTCACCAGGACTCAC 80
CACTTCAAGGAGGGGTCCCTCAGAGCACCTGCCATACCCC 120
TGCACAGTGCTGCGGCTGAGTTGGCTTCAAACCATCCAAG 160
AGGCCCAGAAGCAAACCTGGAGGTGAGACCCAAAGAAAGC 200
TGGAACCATGCTGACTTTGTACACTGTGAGGACACAGAGT 240
CTGTTCCCTGGAAAGCCCAGTGTCAACGCAGATGAGGAAGT 280
CGGAGGTCCCCAAATCTGCCGTGTATGTGGGGACAAGGCC 320
ACTGGCTATCACTTCAATGTTCATGACATGTGAAGGATGCA 360
AGGGCTTTTTTCAGGAGGGCCATGAAACGCAACGCCCGGCT 400
GAGGTGCCCCCTTCGGGAAGGGCGCTGCGAGATCACCCGG 440
AAGACCCGGCGACAGTGCACGGCCTGCCCGCTGCGCAAGT 480
GCCTGGAGAGCGCCATGAAGAAGGAGATGATCATGTCCGA 520
CGAGGCCGTGGAGGAGAGGGCGGGCTTGATCAAGCGGAAG 560
AAAAGTGAACGGACAGGGACTCAGCCACTGGGAGTGCAGG 600
GGCTGACAGAGGAGCAGCGGATGATGATCAGGGAGCTGAT 640
GGACGCTCAGATGAAAACCTTTGACACTACCTTCTCCCAT 680
TTCAAGAATTTCCGGCTGCCAGGGGTGCTTAGCAGTGGCT 720
GCGAGTTGCCAGAGTCTCTGCAGGCCCCATCGAGGGAAGA 760
AGCTGCCAAGTGGAGCCAGGTCCGGAAAGATCTGTGCTCT 800
TTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGCAGTG 840
TCTGGAACCTACAAACCCCCAGCCGACAGTGGCGGGAAAGA 880
GATCTTCTCCCTGCTGCCCCACATGGCTGACATGTCAACC 920
TACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTCATCT 960
CCTACTTCAGGGACTTGCCCATCGAGGACCAGATCTCCCT 1000
GCTGAAGGGGGGCGGCTTTCCGAGCTGTGTCAACTGAGATT 1040
AACACAGTGTTCAAACGGGAGACTGGAACCTGGGAGTGTG 1080
GCGGGCTGTCTTACTGCTTGGGAAGACACTGCAGGTGGCTT 1120
CCAGCAACTTCTTACTGGAGCCCATGCTGAAATTCCACTAC 1160
ATGCTGAAGAAGCTGCAGCTGCATGAGGAGGAGTATGTGC 1200
TGATGCAGGCCATCTCCCTCTTCTCCCCAGACCGCCAGG 1240
TGIGCTGCAGCACCGGTGGTGGACCAGCTGCAGGAGCAA 1280
TTCCCATTTACTCTGAAGTCTTACATTGAATGCAATCGGC 1320
CCCAGCTGCTCATAGGTCTTGTTCCTGAAGATCATGGC 1360
TATGCTCACCGAGCTCCGCAGCATCAATGCTCAGCACACC 1400
CAGCGGCTGCTGCGCATCCAGGACATACACCCCTTTGCTA 1440

```

Fig. 7

9/15

CGCCCCTCATGCAGGAGTTGTTTCGGCATCACAGGTAGCTG 1480
AGCGGCTGCCCTTGGGTGACACCTCCGAGAGGCAGCCAGA 1520
CCCAGAGCCCTCTGAGCCGCCACTCCCCGGGCAAGACAGA 1560
TGGACACTGCCAAGAGCCGACAATGCCCTGCTGGCCTGTC 1600
TCCCTAGGGAATTCCCTGCTATGACAGCTGGCTAGCATTCC 1640
TCAGGAAGGACATGGGTGCCCCCACCAGTTTCAGTCT 1680
GTAGGGAGTGAAGCCACAGACTCTTACGTGGAGAGTGCAC 1720
TGACCTGTAGGTCAGGACCATCAGAGAGGCAAGGTTGCC 1760
TTTCCTTTTAAAAGGCCCTGTGGTCTGGGGAGAAATCCCT 1800
CAGATCCCACTAAAGTGTCAAGGTGTGGAAGGGACCAAGC 1840
GACCAAGGATAGGCCATCTGGGGTCTATGCCACATAACC 1880
ACGTTTGTTCGCTTCCTGAGTCTTTTCATTGCTACCTCTA 1920
ATAGTCCCTGTCTCCCACTTCCCACTCGTTCCCTCCTCTT 1960
CCGAGCTGCTTTGTGGGCTCAAGGCTGTACTCATCGGCA 2000
GGTGCATGAGTATCTGTGGGAGTCTCTAGAGAGATGAGA 2040
AGCCAGGAGGCTGCACCAAATGTCAGAAGCTTGGCATGA 2080
CCTCATTCGGGCCACATCATTCGTGTCTCTGCATCCATT 2120
TGAACACATTATTAAGCACTGATAATAGGTAGCCTGCTGT 2160
GGGGTATACAGCATTGACTCAGATATAGATCCTGAGCTCA 2200
CAGAGTTTATAGTTAAAAAACAAACAGAAACACAAACAA 2240
TTTGGATCAAAAGGAGAAAATGATAAGTGACAAAAGCAGC 2280
ACAAGGAATTTCCCTGTGTGGATGCTGAGCTGTGATGGCA 2320
GGCACTGGGTACCCAAGTGAAGGTTCCCGAGGACATGAGT 2360
CTGTAGGAGCAAGGGCACAACCTGCAGCTGTGAGTGGTG 2400
TGTTGTGATTTGGGTAGGTAGGTCTGTTTGCCACTTGATG 2440
GGGCCGGGTTFGTTCCTGGGGCTGGAATGCTGGGTATGC 2480
TCTGTGACAAGGCTACGCTGACAATCAGTTAAACACACCG 2520
GAGAAGAACCATTACATGCACCTTATATTTCTGTGTACA 2560
CATCTATTCTCAAAGCTAAAGGGTATGAAAGTGCCTGCCT 2600
TGTTTATAGCCACTTGTGAGTAAAAATTTTTTTCATTTT 2640
CACAAATTATACTTTATATAAGGCATTCCACACCTAAGAA 2680
CTAGTTTGTGGAAATGTAGCCCTGGGTTTAATGTCAAATC 2720
AAGGCAAAAGGAATTAATAATGTACTTTTGGCTAAAAAA 2760
AA 2800
AA 2802

Fig. 7 (cont.)

10/15

MTVTRTHHFKEGSLRAPAIPLHSAAAELASNHPRGPEANL 40
EVRPKESWNHADVFHCEDTESVPGKPSVNADEEVGGPQIC 80
RVC GDKATGYHFNVMTCEGCKGFFRRAMKRNARLRCPFRK 120
GACEITRKTRRQCQACRLRKCLESGMKKEMIMSDEAVEER 160
RALIKRKKCERTGTQPLGVQGLTEEQRMIRELMDAQMKT 200
FDTTFSHFKNFRLPGVLSSGCELPESLQAPSREEAAKWSQ 240
VRKDLCSLKVSLQLRGEDGSVWNYKPPADSGGKEIFSLLP 280
HMA DMSTYMFKGIISFAKVISYFRDLPIEDQISLLKGA AF 320
ELCQLRFNTVFNAETGTWECGRLSYCLEDTAGG FQQLLE 360
PMLKFHYMLKKLQLHEEEYVLMQAISLFS PDRPGVLQHRV 400
VDQLQE QFAITLKS YIECNRPQPAHRFLFLKIMAMLT ELR 440
SINAQHTQ RLLRIQDIHPFATPLMQELFGITGS. 474

Fig. 8

11/15




Fig. 9

12/15




Fig. 10

SUBSTITUTE SHEET (RULE 26)

13/15




Fig. 11

14/15




Fig. 12

15/15




Fig. 13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01548

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/72, C12N 15/10, A61K 38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, C12N, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9622390 A1 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES), 25 July 1996 (25.07.96), the claims, seq. 1	1-19,21-22, 24-27
A	--	20,23
X	WO 9317041 A1 (THE GENERAL HOSPITAL CORPORATION), 2 Sept 1993 (02.09.93), the claims, seq. ID No 1	1-27
X	WO 9636230 A1 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES), 21 November 1996 (21.11.96)	1-27

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 December 1998

Date of mailing of the international search report

21-12-1998

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/01548

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9306215 A1 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES), 1 April 1993 (01.04.93) --	1-19,21-22
X	Nucleic Acids Research, Volume 22, No 1, 1994, Darrin P. Smith et al, "A novel nuclear receptor superfamily member in Xenopus that associates with RXR, and shares extensive sequence similarity to the mammalian vitamin D3 receptor" page 66 - page 71 --	1-19
X	WO 8909223 A1 (ARCH DEVELOPMENT CORPORATION), 5 October 1989 (05.10.89), figure 5 --	1-19,21-22
P,X	EMBL, Databas Genbank/DDBJ, accession no. AF031814, Kliwer S.A. et al: "An orphan Nuclear Receptor Activated by Pregnanes Defines a Novel"; & Steroid Signaling Pathway, Cell 92:73-82(1998), 1-1709 -- -----	1-27

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE98/01548

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 28-30
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/12/98

International application No.

PCT/SE 98/01548

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9622390 A1	25/07/96	AU 4693496 A CA 2210679 A EP 0822991 A	07/08/96 25/07/96 11/02/98
WO 9317041 A1	02/09/93	AT 172247 T AU 684458 B AU 3728393 A CA 2117491 A DE 69321580 D EP 0628054 A,B JP 7504416 T US 5686574 A US 5710017 A US 5756448 A	15/10/98 18/12/97 13/09/93 02/09/93 00/00/00 14/12/94 18/05/95 11/11/97 20/01/98 26/05/98
WO 9636230 A1	21/11/96	AU 5426596 A	29/11/96
WO 9306215 A1	01/04/93	AU 2579692 A CA 2115452 A EP 0609240 A US 5571696 A US 5696233 A US 5710004 A	27/04/93 01/04/93 10/08/94 05/11/96 09/12/97 20/01/98
WO 8909223 A1	05/10/89	EP 0407462 A JP 3504438 T US 5614620 A	16/01/91 03/10/91 25/03/97

Form PCT/ISA/210 (patent family annex) (July 1992)